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Phospholipids are widely used as active ingredients and pharmaceutical excipients. In
oral applications they have recently become attractive due to the variety of functions they
could perform in formulations; exceptional biocompatibility of phospholipids in general,
and phosphatidylcholine (PC) in particular.
1.1.1 Phospholipid Classes
There are two main classes of natural phospholipids which occur in sufficient quantities
to allow industrial manufacturing and application: glycerophospholipids with a glycerol
and sphingophospholipids with a sphingosine backbone, latter being out of the scope of
this work.
Glycerophospholipids (further referred as phospholipids) are the derivatives of triacyl-
glycerols with one fatty acid substituted by a phosphoric acid ester of an amino al-
cohol (e.g. choline, ethanolamine), a polyol (e.g. glycerol, inositol) or, in the case of
phosphatidic acid, by free phosphoric acid, resulting in phosphatidylcholine (PC), phos-
phatidylethanolamine (PE), etc., respectively. Depending on the structure of polar the
head and medium pH, phospholipids would have different ionization status and, thus,
net charge. PC and PE are zwitterionic and have neutral charge at pH 7, while phos-
phatidylglycerol and -inositol (PG and PI) are negatively charged (Figure 1).
The most common phospholipid is phosphatidylcholine. Phosphatidylcholines repre-
sent the most abundant lipid class in mammalian membranes and a major membrane
component in eukaryotic organisms. Therefore, it is also the main component of lecithin.
United States Pharmacopeia (USP) defines lecithin as a “complex mixture of acetone-
insoluble phosphatides, which consist chiefly of phosphatidylcholine, phosphatidylser-
ine, and phosphatidylinositol, combined with various amounts of other substances such
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Figure 1. Molecular structures and ionization status of common phospholipids.
as triglycerides, fatty acids, and carbohydrates, as separated from the crude vegetable
oil source. It contains NLT 50.0% of acetone-insoluble matter”. There is, however, slight
confusion with a term “lecithin”, since originally it was assigned to the pure PC prece-
dent from egg-yolk, and it is still used in some medicinal literature and documents of
health authorities in regard to PC, although it does not comply with modern USP defini-
tion of lecithin. In the food and cosmetic industry “lecithin” became a tradename for a
mixture of phosphatides as a nutrition supplement. In this work, it is referred to lecithin
as a purified or impurified product of extraction from the raw material, which can be
considered as an excipient on its own or starting material for further separation of phos-
phatidylcholine.
1.1.2 Phospholipid Sources and Processing
Phospholipids may be obtained from natural sources or by various synthesis routes. Syn-
thetic phospholipids have defined desirable fatty acids compositions and polar head
groups. Historically, they were used in biophysical and biochemical fields as models
to understand mechanistic aspects of bio-membranes. Further, synthetic phospholipids
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were designed to optimize drug targeting of parenteral dosage forms, such as liposomes.
There are several approaches to synthetize diacyl-PC using organic chemical synthesis
and/or enzymatic synthesis steps. Apart from defined composition (i.e. exact phase
transition temperature), synthetic phospholipids have elevated costs, due to numerous
and complex steps of production, low yields and necessity to recycle hazardous solvents,
used in the synthesis.
Figure 2. World supply of soybean, rapeseed and sunflower in the tie period between 2012-2017.
Source: United States Department of Agriculture, National Agricultural Statistics Ser-
vice www.nass.usda.gov.
Phospholipids obtained from natural sources are defined as natural phospholipids. Main
sources of rawmaterials are soybean, rape seeds, wheat germs, sunflower, egg yolk, milk
and krill. Due to their importance in a food industry, these materials are producedworld-
wide on a very large scale (Figure 2), and there is clearly adequate supply also for phar-
maceutical industry needs.
The phospholipids composition and fatty acids profiles depend on the raw material
sources (Table 1 and Table 2) as well as may slightly vary due to climatic conditions
during plant maturation and its genetic origin. Therefore, there should be a strict qual-
ity control of the raw material applied, as well as validated production methods used
to guarantee reproducibility of phospholipid excipient batches obtained from lecithin by
extraction and chromatographic purification.
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Table 1. Phospholipid composition of vegetable de-oiled lecithins, %. Adopted from Hoogevest
and Wendel, 2014.
Phospholipid Soybean Sunflower seed Rapeseed
PC 20-22 20-26 23-31
PE 16-22 4-10 9015
PI 13-16 15-19 15-18
PA 5-10 2-5 5-10
LPC <3 <3 <3
Table 2. Fatty acid composition of typical batches or vegetable de-oiled lecithins, area%. Adopted
from Hoogevest and Wendel, 2014.
Fatty acid Soybean Sunflower seed Rapeseed
C14:0 0.1 0.1 0.1
C16:0 21 16 10
C18:0 4.7 5.3 0.8
C18:1 9.9 21 49
C18:2 57 54 31
C18:3 5.0 0.2 4.4
C20:0 0.1 0.5 0.1
C22:0 0.4 1.5 0.1
To explain the production process of natural phospholipid excipients from plant oil, soy-
bean lecithin is taken as an example (Figure 3).
Crude soybean lecithin, is a result of degummed soybean oil, extracted from soybeans,
which further serves as a starting material for production of lecithin with high PC con-
tents. High yields are achieved by extraction methods using non-toxic solvents, acetone
and ethanol, followed by chromatographic purification procedures and appropriate sol-
vent removal, which is often recycled and reused (Wendel, 2001).
Lecithins with different PC-fractions (PC 20-80%) and up to pure PC (98%) can be ob-
tained by selecting appropriate sequential extraction and purificationmethods. Although,
phospholipid composition and fatty acids ratios would slightly change between lecithins
with different PC fractions, there are 5 fatty acids types, which account 95% of the to-
tal fatty acid composition. These are palmitic acid (C16:0), stearic acid (C18:0), oleic
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Figure 3. Flow sheet of lecithin producing unit. Crude soybean oil is heated in the preheater, 1, to
80°C, mixed with 2% water in the proportion control unit, 2, and intensively agitated in
3. The mixture goes to a dwelling container, 4, and is then centrifuged after a residence
time of 2–5 min. The degummed oil flows without further drying to the storage tanks.
The lecithin sludge is dried in the thin-film evaporator, 6, at 100°C and 6 kPa (60 mbar)
for 1–2 min and is discharged after cooling to 50–60°C in the cooler, 8. 9 and 10 are
the condenser and vacuum pump, respectively. Reprinted fromWendel, 2001 with kind
permission of John Wiley and Sons.
acid (C18:1), linoleic acid (C18:2) and linolenic acid (C18:03). Moreover, inter-batch vari-
ability is low, resulting in high quality pharmaceutical excipients, which comply with
pharmacopeia and regulatory requirements for parenteral and other specific formula-
tions (Hoogevest and Wendel, 2014).
1.1.2.1 Hydrogenated lecithin
Natural phospholipid mixtures (lecithins) contain high levels of unsaturated fatty acids
(Table 2). The acyl chain unsaturation, lowers the phase transition temperature from gel
to liquid crystalline state to below zero degrees, thus, at ambient and physiological tem-
peratures these phospholipids form flexible structures upon hydration, which are suit-
able for specific pharmaceutical technological applications (e.g. liposomes). However, in
order to achieve more physically stable liposome formulations (Senior and Gregoriadis,
1982), or address other technological needs (Fini et al., 2008), phospholipids with higher
phase transition temperatures are required.
The catalytic hydrogenation of natural phospholipids is performed. In this process, the
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Figure 4. Specificity of phospholipases and lipases towards the phospholipid structure. Adopted
from Gunstone, 2008.
unsaturated fatty acids are saturated by hydrogen gas in a catalytic reaction involving
metal catalysts (e.g. nickel, palladium, and platinum) bound to porous carrier, typically
in a heterogeneous system (Baer, 1965; Jacini, 1954). The attempts to produce partially
hydrogenated phospholipids have not been successful so far, since it is very difficult to
terminate hydrogenation reproducibly at a defined point of hydrogen uptake. Therefore,
only fully saturated products are available (Gunstone, 2008). As a result, resulting phos-
pholipids are more stable against oxidation, but at the same time less soluble in fats and
oils. Another effect of hydrogenation is a complete elimination of most of the natural
pigments, resulting in white to off-white free-flowing phospholipid powders.
1.1.2.2 Enzyme-modified phospholipids
Due to fast recent advances in biotechnology, enzyme catalysed reactions serve as a vi-
able alternative to organic chemical synthesis reactions, nowadays. Thus, the use of en-
zymes for phospholipid modifications has been growing not only in academic research
but also in industry (Gunstone, 2008). There is a number of reasons for the fast-growing
use of enzymes for polar lipid modification, such as milder reaction conditions, less en-
vironmental pollution, better specificity for improved quality, and higher efficiency of
reactions. For industrial applications, the economic balance of the processes is, however,
the key factor, and there has been a steady advance in enzyme production and enzyme
technology in the past few years as well.
There is a number of bond-specific enzymes, which can be used for different modification
purposes of PL ester bonds (Figure 4). For acyl modifications, the phospholipase A1
and A2 (PLA1 and PLA2, respectively) are specific and position selective (sn-1 and sn-2,
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respectively). The triacylglycerol lipases in general can also be used for such purposes, in
particular formodifications at the sn-1 position, however there is no lipase known to react
selectively at the sn-2 position. For polar group modification, phospholipase D (PLD) is
the only potential enzyme known, while phospholipase C (PLC) can hydrolyse the bond
between the glycerol OH group and the phosphate group. The examples of enzyme-
modified natural phospholipids are monoacyl-phospholipids (lyso PC, LPC), soy PE, soy
and egg PG, and their saturated analogues (Hoogevest and Wendel, 2014).
1.1.3 Properties and Characterization
Phospholipids have a bipolar, amphiphilicmolecular structure, which consists of lipophilic
part in the form of two fatty acids and a hydrophilic group in the form of a phosphoric
acid based esters. Due to their amphiphilic character, phospholipids show a tendency to
form bilayers or micelles and liposomes, once hydrated. As a result, they find many ap-
plications in foods, cosmetic and pharmaceutical products as natural emulsifiers, wetting
and dispersing agents.
The physical chemistry of polar lipids, including phospholipids, has been thoroughly re-
viewed in a number of textbooks and individual chapters (Cevc, 1993; Larsson, 1994).
Most phospholipids are soluble in chloroform, dichloromethane, hexane, methanol, etha-
nol, isopropanol, pyridine and their mixtures. The mixtures of hexane and isopropanol
are commonly used in HPLC for the dissolution and elution of phospholipids are, some-
times with a small portion of water added (Letter, 1992). Water and aqueous solutions,
on the other hand, are poor solvents for phospholipids; although phospholipids disperse
readily in aqueous media, the maximum solubility of double-chain phosphatidylcholines
with 14–18 carbon atoms in water at room temperature is only about 10
–10
M (Cevc, 1993).
Zwitterionic phospholipids contain both a negative and a positive charge under physi-
ological conditions. Depending on the medium pH they can be cationic or zwitterionic.
Despite the low water solubility, it is possible to attribute an apparent acid dissociation
constant, pKa, to the different functional groups (e.g. phosphate, amine, carboxyl moi-
eties) in the phospholipid polar head group (Boggs, 1987; Marsh, 1990). Due to the sur-
face effects of phospholipids, the pKa values of these groups are slightly different from
the intrinsic values in bulk water. However, due to the sensitive experimental procedures
employed, values also differ depending on the determination method applied (Koynova
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and Caffrey, 1998). Nevertheless, it has been possible to determine apparent pKa val-
ues from the titration of the gel-to-liquid bilayer transition temperature at different bulk
proton concentrations, and some pKa values are listed in Table 3 for the most common
double-chain phospholipids (Tatulian, 1993).
Table 3. Apparent pKa values of ionizable groups of some common double-chain phospholipids.
a
Phospholipid Medium Temperature (°C)
b





DLPA 0.1 M NaCl Tt 4.0, 8.1 - -
DMPA 0.1 M NaCl Tt 4.0, 8.5 - -
DLPE Triton X-100 40 ~1 - 9.8
DMPE 0.1 M NaCl Tt 1.7 - 11.2
DMPC 0.1 M HCl Tt ~1 - -
DPPC 0.1 M HCl Tt ~1 - -
DMPG 0.1 M NaCl Tt 3.5 - -
DPPG 0.1 M NaCl Tt 3.1 - -
DMPS 0.1 M NaCl Tt 2.6 5.5 11.6
DPPS 0.1 M NaCl 25 NA 4.6 NA
a
The enthalpy of protonation is much higher for the amino group than for the phosphate and
carboxylate groups and it is, thus, more dependent on the temperature (Marsh, 1990).
b
Tt is the temperature deduced at the gel-to-liquid phase transition from titration of the transition
temperature. NA = data not available; – = not applicable. Adopted from Gunstone, 2008.
The protonation / deprotonation of the phospholipid head groups caused by a pH change
in the aqueous environment has a great impact on the physical properties of the phospho-
lipid molecule. A change of charge sign and/or net charge may influence the molecular
conformation and the overall polarity, which may further affect phase transitions, hydra-
tion/swelling, and interactions with ions and solutes, such as peptides and proteins, and
the colloidal stability of aqueous dispersions of phospholipid aggregates. Furthermore,
changes in pH have also an influence on the hydrolytic stability of the phospholipids
(Grit, Underberg, and Crommelin, 1993).
Furthermore, polar lipids may be divided into three different classes depending on their
interaction with bulk water and their behaviour in the water–air interface (Small, 1968).
The Class I compromises the insoluble, non-swelling lipids; Class II includes the insol-
uble and swelling lipids; and Class III describes the soluble lipids. According to this
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classification, the double-chain phospholipids belong to Class II while the single-chain
phospholipids – to Class III. The Class II lipids are particularly interesting from a phase
behavioural perspective. As it is previously mentioned, they are virtually insoluble in
water, however the interactionwithwater or swelling inwater in temperature-dependent
fashion results in the formation of various liquid crystalline phases.
1.1.4 Polymorphism
The term ‘polymorphism’ is traditionally used to indicate that more than one (liquid)
crystalline phase is formed by a substance. Phospholipids are most often regarded fully
or partially hydrated, therefore present a polymorphic behaviour.
Thermotropic mesomorphism
On heating of phospholipids, an endothermic transition is observed at a temperature
well below the true melting point of the material. At this transition a change of solid
state occurs, resulting in different liquid-crystalline, or mesomorphic states. In these me-
somorphic states the hydrocarbon chains have a conformation similar to that observed
in liquid hydrocarbons whilst the polar moieties of the molecules hold the structure to-
gether in some particular manner. Thus, at this crystal to liquid-crystal transition melting
of the hydrocarbon chains occurs. The formation of different phases under effect of tem-
perature is called thermotropic mesomorphism.
In contrast to phospholipid-water rich systems, there are just few records regarding the
structure ofmesophases of non-hydrated (i.e. anhydrous) phospholipids. In 1960s tempe-
rature-resolved X-ray diffraction techniques were applied to characterize mesophases of
anhydrous egg lecithin (Luzzati, Gulik-Krzywicki, and Tardieu, 1968; Small, 1967). Luz-
zati et al. have published a detailed crystallographic examination of the phases obtained
in the egg-yolk lecithin with water content less than 6% (w/w) (Figure 5).
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Figure 5. The high-temperature high-lipid region of the egg lecithin-water system; the one-phase
regions are hatched: the limits are not precisely known; two or three phases are usually
observed in the intermediate regions. The phases noted are: C : three-dimensionally
crystalline; Lβ : lamellar, with stiff hydrocarbon chains packed in an hexagonal subcell
(phase Lβ was never found quite pure in this system); Pδ : two-dimensional centred
rectangular lattice, hydrocarbon chains partly ordered; Q : cubic, body centred, disor-
dered hydrocarbon chains. Adopted from Luzzati et al., 1968, with a kind permission
from Springer Nature.
Lyotropic mesomorphism
The addition of solvents can also induce phase transition in liquid crystalline materials,
this phenomenon is called lyotropic mesomorphism. The lyotropic phases obtained are
thus a function of both, water content and temperature. The characteristic phase transi-
tion temperature (To), depends on numerous factors, e.g. length, saturation and symme-
try of hydrocarbon chains, chemical link between the chains and the polar headgroup,
phospholipid heterogeneity, medium composition and pH (Koynova and Caffrey, 1998).
As it has been reviewed by Koynova and Tenchov (2013), a generalized phase sequence
of thermotropic phase transitions in membrane lipids (i.e. fully hydrated phospholipids
and glycolipids) may be written as follows (Tenchov, 1991):
Lc⟷ Lβ⟷ Lα⟷ Q
[B]∣∣ ⟷ H∣∣⟷ Q[M]∣∣ ⟷ M∣∣
On heating, a lamellar crystalline (subgel) Lc phase transforms into lamellar gel Lβ phase;
the latter phase undergoes a melting transition into the lamellar liquid-crystalline Lα
phase. Upon further increase in temperature, a series of mesomorphic phase transitions
follow the sequence Lα—bilayer cubic Q
[B]∣∣ —inverted hexagonal H∣∣—inverted micellar
cubic Q
[M]∣∣ —micellar M∣∣. Some lipids can form two or more modifications of a given
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phase, for example, gel phases of different structures (interdigitated, tilted, rippled; Fig-
ure 6 C, D, E) and bilayer cubic phases of different topology (Figure 6 P, Q, R).
With the increase inwater content at constant temperature, themesomorphic lipid phases
arrange themselves in the following sequence (Seddon, 1990):
inverted phases(M∣∣,Q[M]∣∣ ,H∣∣,Q[B]∣∣ )⟷ Lα⟷ normal phases(Q[B]I ,HI ,Q[M]I )⟷
micellar solution⟷ monomers
Typically, double-chain lipids only form Lα and inverted phases, whereas single-chain
lipids can also form normal phases and micellar solutions. This phase sequence is ra-
tionalized by the effect of water content on the effective shape of the lipid molecules.
Low hydration levels lead to tighter packing and smaller-surface molecular areas of lipid
polar head groups, resulting in negative interfacial curvature and a tendency to form in-
verted phases. With an increase in water content, the surface molecular area expands;
consequently, the concave interfaces of inverted phases sequentially transform into the
flat interface of the Lα phase and into the convex interfaces of the normal mesomorphic
phases. Further dilution results in dissipation of periodic lipid structures and formation
of micellar solutions (and eventually monomer solutions at high dilutions, below the
critical micellar concentration, CMC) (Koynova and Tenchov, 2013).
Phosphatidylcholines have been extensively studied in regard to aqueous interaction and
phase properties, because of their importance in biological membrane functions, as well
as interest in liposome development (Larsson, 1994). It has been illustrated by numer-
ous publications in the field, reviewed and indexed by Koynova and Caffrey, 2002, who
presented more than 2000 phase diagrams of various lipids, including phospholipids.
Most of the presented phase diagrams referred to binary (two-component, i.e. phospho-
lipid–water) temperature-composition phase diagrams, but also more complex (ternary,
quaternary) phase diagrams were listed.
1.1.4.1 Experimental techniques for studying the phase behaviour of phospholipids
There is a great variability of experimental techniques to determine the physical proper-
ties of a phospholipid system. Some of the most important techniques are polarized light
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Figure 6. Structures of lipid phases. I. Lamellar phases: (A) subgel, Lc; (B) gel, Lβ; (C) interdigi-
tated gel, L
[int]
β ; (D) gel, tilted chains, Lβ’; (E) rippled gel, Pβ’; (F) liquid crystalline, Lα
. II. Micellar aggregates; (G) spherical micelles, MI ; (H) cylindrical micelles (tubules);
(J) disks; (K) inverted micelles, MI I; (L) liposome; III. Non-lamellar liquid-crystalline
phases of various topology; (M) hexagonal phase HI ; (N) inverted hexagonal phase
HI I; (O) inverted micellar cubic phase QI I
[M]
; (P) bilayer cubic (QI I) phase Im3m; (Q)
bilayer cubic phase Pn3m; (R) bilayer cubic phase Ia3d. (Koynova and Tenchov, 2013).
microscopy, X-ray crystallography, NMR spectroscopy, rheology, and differential scan-
ning calorimetry.
The easiest way to characterize a sample is to observe if it scatters thel light by ocular
inspection or turbidity measurement using a spectrophotometer. Isotropic micellar solu-
tions and cubic liquid crystals are clear and transparent, whereas the anisotropic liquid
crystals scatter light and appear more or less cloudy (Holmberg, 2003).
Polarized light microscopy, can be used to judge if a sample is isotropic or not, as well
as to distinguish between the different anisotropic phases, such as lamellar and hexago-
nal phases. It is often possible to guess the phase structure from the appearance in the
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microscope, when composition is known, however, for precision the structure must be
concluded by a more reliable technique. Traditionally, X-ray diffraction has been used to
accomplish this (Fontell, 1981), complemented by various NMR techniques (Holmberg,
2003; Lindman, 1987) in recent years.
Viscosity measurements may provide useful information on the rheological properties of
phospholipid–water systems in a relatively simple manner. For micellar solutions, the
viscosity is generally related to the micelle size and shape. The most important effect is
the dramatic increase in viscosity occurring on formation of rod-like micelles. Generally,
the viscosity of liquid crystals increases in the order lamellar < hexagonal < cubic. For
the lamellar phase, the lipid bilayers can easily move over each other, but motion per-
pendicular to the layered structure is difficult. For hexagonal phases (both normal and
reversed), motion along the cylinders is easy, but motion perpendicular to the cylinders
is difficult since it involves changes in cylinder packing. Finally, for cubic phases there
is no easy flow direction, since a three-dimensional structure exists and often a complex
rheological behaviour is observed (e.g. shear thinning at low shear rates, increased vis-
cosity at high shear rates, etc.).
Differential scanning calorimetry (DSC) is a common technique for the thermal analysis
Figure 7. DSC thermogram of 1,2-diacyl-L-phosphatidylcholine monohydrates: (a) distearoyl-;
(b) dipalmitoyl-; (c) dimyristoyl-; (d) dilauroyl-; (e) dicapryl-; (f) 1-stearoyl-2-oleoly; (g)
egg yolk. Adopted from Chapman. et al. 1967, with
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of pure and, ideally, anhydrous phospholipids, used for example for determination of
the melting point, but more often for the determination of chain-melting temperatures
and phase equilibria in binary phospholipid–water mixtures (Figure 7) (Ladbrooke and
Chapman, 1969).
Various infra-red spectroscopy techniques may be used to understand molecular interac-
tions during phospholipid phase transitions, interactionswith proteins and drugmolecules
(Bensikaddour et al., 2008; Fookson and Wallach, 1978; Fringeli, 1981; Yang, Kamiya,
and Goto, 2012). Detailed assignment of absorption wavelengths for anhydrous 1,2-
distearoyl-L-phosphatidylcholine crystallized from chloroform / diethyl ether has been
given by Chapman, Williams, and Ladbrooke, 1967.
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1.2 Phospholipids in Oral Drug Delivery
Phospholipids become increasingly important as formulation excipients, as well as ac-
tive ingredients. Due to the diversity and the biocompatibility, phospholipids appli-
cation spectrum within oral drug formulation comprised bioavailability enhancement
of drugs with low aqueous solubility and/or low membrane penetration potential, as
well as protection of sensitive active agents from degradation in the gastrointestinal tract
(GIT), reduction of gastrointestinal side effects of non-steroidal anti-inflammatory drugs
and taste masking of bitter drugs. Technological strategies to achieve these effects are
highly diverse and offer various possibilities of liquid, semi-liquid and solid lipid-based
formulations for drug delivery optimization.
1.2.1 Phospholipids fate after oral ingestion
The fate of phospholipid-based formulations inside the gastrointestinal tract and their
impact on drug absorption had been discussed in detail (Chakraborty et al., 2009, Fricker
et al., 2010 and Porter, Trevaskis, and Charman, 2007). Shortly, the digestion of lipids be-
gins in the oral cavity through exposure to lingual lipases and continues in the stomach
through the effects of both lingual and gastric enzymes. The stomach further contributes
to lipid processing bymechanical mixing, which when combinedwith the presence of the
amphiphilic products of initial lipid digestion (diglycerides and fatty acids) facilitates for-
mation of a crude emulsion. In the small intestine, pancreatic lipase completes the break-
down of tridiglycerides into diglyceride, monoglyceride and fatty acid. Pancreatic lipase
acts primarily at the sn-1 and sn-3 positions of triglycerides to produce 2-monoglyceride
and free fatty acid. The presence of exogenous lipids in the small intestine also stimulates
secretion of endogenous biliary lipids, including bile salt, phospholipids and cholesterol
from the gall bladder. In the presence of raised bile salts concentrations, the products of
lipid digestion (monoglyceride, fatty acid and lysophospholipids) are subsequently in-
corporated into a series of colloidal structures, including multilamellar and unilamellar
vesicles, mixed micelles and micelles. Together these species significantly expand the
solubilization capacity of the small intestine for lipid digestion products and, potentially,
for the incorporated drugs (Figure 8).
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The primary mechanisms by which lipid-based drug formulations enhance drug solu-
bilization in GI tract are by presentation as a solubilized formulation (thereby avoiding
solid-state limitations) and by induction of changes to the character of the GI environ-
ment (Porter, Trevaskis, and Charman, 2007). Upon the dispersion of the lipid based for-
mulation, oily ester components are subjected to the digestion in the small intestine, thus
the solubilization capacity of the formulation may change. This can lead either to drug
precipitation, resulting in the loss of advantage of the lipid formulation, or in contrary,
to the formation of endogenous colloidal phases such as vesicles and micelles, that in-
creases the solubilization of co-administered drug in the small intestine (Yeap, Trevaskis,
and Porter, 2013, Yeap et al., 2013).
Figure 8. Lipid digestion and drug solubilization in the small intestine. Reprinted from Porter et
al., 2008, with kind permission from Elsevier.
In general, as it has been thoroughly reviewed by Porter (Porter et al., 2008), non-digestible
lipids such as mineral oils (e.g. liquid paraffin) and sucrose polyesters (which remain es-
sentially unabsorbed in the intestinal lumen), reduce drug absorption by retaining part
of the co-administered drug in the undigested formulation and impeding transfer to the
colloidal species in the luminal aqueous phase where absorption is thought to occur.
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Therefore, digestible lipids such as soybean oil, corn oil or olive oil are typically pre-
ferred for lipid solution formulations. Bioavailability improvement is usually attributed
to enhanced drug solubilization in the colloidal species formed by digestion of the lipid
vehicle and intercalation of the lipid digestion products into endogenous bile salts and
phospholipid micellar structures. In addition to the digestibility of the lipid vehicle, the
nature of the lipid used, in terms of fatty acid chain length, the degree of unsaturation
and the lipid class, may also alter the oral bioavailability of poorly water-soluble drugs.
1.2.1.1 In vitro lipolysis model
Due to the complexity of the events taking place after ingestion of lipid based formu-
lations, conventional dissolution, or dispersion, tests are often not feasible for in vitro
evaluation of drug release, because these tests do not take into account that excipients
can be prone to lipase catalysed hydrolysis in the gastrointestinal tract. Therefore,in vitro
digestion models, also known as in vitro lipolysis models, are used to assess the destiny
of lipid based formulation in vivo (Larsen, Sassene, and Müllertz, 2011).
The existing models are simulating lipid digestion in the upper small intestine. Buffers
with physiological concentrations of bile salts, phospholipids are used as releasemedium.
Lipid-based systems containing drug are mixed and incubated at 37°C. The levels of bile
salts and phospholipid are selected to simulate either the fasted or the fed state, depend-
ing on the purpose of the study. The lipolysis is initiated by the addition of pancreatic en-
zymes (i.e. pancreatic extract). The action of pancreatic lipase and other esterases present
in the pancreatic extract induces the hydrolysis of triacyl glycerides and other excipients,
releasing free fatty acids, which are neutralized by addition of sodium hydroxide by the
pH-stat. Furthermore, in order to prevent FA accumulation on the surface of the lipid
droplet and thus, inhibition of the activity of pancreatic lipase, they are precipitated from
the medium by addition of calcium ions, which form insoluble calcium fatty acid soaps
(Figure 9).
Samples are collected at different time points and lipolysis is immediately inhibited by
using 4-bromobenzeneboronic acid solution.
The samples are separated by ultracentrifugation into three different phases, namely, oil,
micellar and pellet phase (Figure 10). The oil phase on the top of the tube is generally
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Figure 9. In vitro lipolysis set-up. 1 thermostatic double wall reaction vessel; 2 pH-stat with the
auto burette for the addition of NaOH; 3 peristaltic pump for addition of CaCl2; 4 the
computer with the software for the titration experiments. The temperature is monitored
during the experiment with a thermocouple. The experiment is performed under con-
tinuous agitation at 37°C. Adopted from Larsen, Sassene, and Müllertz, 2011 with kind
permission from Elsevier.
only seen at the beginning of the experiment, and originates from non-digestible formu-
lation. The pellet phase consists of calcium soap of free fatty acid and precipitated drug,
while the micellar phase contains the drug fraction, which, supposedly, is available for
absorption and has been correlated with the bioavailability of drug in vivo.
Furthermore, to assess the nature of colloidal structures formed during “digestion” phase,
cryogenic transmission electron microscopy can be applied on non-centrifuged sample
Figure 10. Different phases of lipid-based formulation after digestion and ultracentrifugation.
Adopted form Müllertz et al., 2010 with a kind permission from John Wiley and Sons.
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(Fatouros, Bergenstahl, and Mullertz, 2007; Kleberg et al., 2010), as well as small-angle X-
ray scattering can be measured online to study the formation of liquid crystalline phases
(Fatouros, Bergenstahl, andMullertz, 2007), while solid state of precipitated drugs can be
analysed by X-ray diffraction (Sassene et al., 2010).
However, whether or not a lipid excipient is subject to gastric and/or pancreatic lipolysis
highly depends on its molecular structure, accessibility of ester bonds and interactions
with water and bile salts, as well as the dosage form. Semi-solid formulations contain-
ing medium chain fatty acids are more readily digested than solid formulations com-
prising long chain fatty acids (Bonnaire et al., 2008). The impact of digestion should be
determined in the final solid dosage form rather than from the pure lipid excipients in
biorelevant media.
1.2.2 Functionality of Phospholipids in Oral Formulations
1.2.2.1 Phospholipids as active ingredients
Beneficial effects of dietary phospholipids (PLs) have been mentioned since the early
1900’s in relation to different illnesses and symptoms, e.g. coronary heart disease, inflam-
mation or cancer. There are several reviews that summarize most common therapeutic
uses of dietary PLs and provide an overview of their approved and proposed benefits
(Gundermann et al., 2016; Küllenberg et al., 2012).
Naturally occurring phospholipids of either plant or animal origin, predominantly con-
tain unsaturated fatty acids in the sn-2 position, such as oleic, linoleic or linolenic acid, or
the proinflammatory arachidonic acid (usually from animal origin) or the anti-inflammatory
eicosapentaenoic acid (usually from marine origin), while the sn-1 position predomi-
nantly carries a saturated fatty acid, such as stearic acid or palmitic acid. In a normal
diet, the daily intake of PC is approximately 2-8 grams (Cohn et al., 2010).
Although there was an extensive research done regarding effects of dietary phospho-
lipids on different groups of illnesses, including human clinical trials supporting positive
effects, the underlying physiological mechanisms have not been fully addressed so far.
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1.2.2.2 Decrease of stomach irritation by NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the activity of the cyclooxygi-
nase (COX enzymes; COX-1 and -2), reducing the production of prostaglandins, which
are responsible for the pain symptoms and the related inflammatory reactions. However,
gastroduodenal ulceration and bleeding are the major limitations to the chronical use of
NSAIDs. The damage to the gastroduodenal mucosa is caused via several mechanisms,
including the topical irritant effect of these drugs on the epithelium, impairment of the
barrier properties of the mucosa, suppression of gastric prostaglandin synthesis, reduc-
tion of gastric mucosal blood flow and interference with the repair of superficial injury
(Wallace, 2000). Though one of the main reasons could be attributed to systemic COX in-
hibition (mainly COX-1), there are several indications, that NSAIDs are also acting locally
on the gastrointestinal mucosa (Langenbach et al., 1995; Ligumsky et al., 1983). Lichten-
berger et al. investigated the hydrophobic lining of the gastric surface by contact angle
analysis (Hills, Butler, and Lichtenberger, 1983; Lichtenberger et al., 1983). It has been
demonstrated that highly hydrophobic, non-wettable properties of the stomach mucosa
were responsible for protecting the underlying epithelium from gastric acid and other lu-
minal toxins. This biophysical property was contributed to the presence of extracellular
lining of zwitterionic phospholipids. On the other hand, aspirin and other NSAIDs have
the ability to transform rapidly, within minutes after administration, the gastric mucosa
from non-wettable to a wettable state, thereby increasing the tissue’s susceptibility to the
corrosive actions of gastric acid (Lichtenberger et al., 2006) (Figure 11).
Based on these findings, the concept of pre-associating NSAIDs with zwitterionic phos-
pholipids prior to administration was introduced (Lichtenberger et al., 1995) and tested
in clinical studies, where a significant decrease in toxicity was found (Anand et al., 1999).
Overall, the drug and phospholipid are dissolved in organic solvent with or without
heating under reflux followed by solvent evaporation. The remaining drug–lipid film
represents the final product, which further could be processed into final dosage forms by
granulation or filling into capsules. It was hypothesized, that the carboxylic function in
acidic NSAIDs (which is undissociated at the acidic pH value of gastric juice) ionized and
associatedwith the quaternary ammonium group of zwitterionic phosphatidylcholine, as
the drug was exposed to the pH gradient within the mucus layer (Lichtenberger et al.,
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Figure 11. Schematic molecular model of putative phosphatidylcholine enriched monolayer at
the interface between the gastric mucus gel and the gastric juice to provide an acid
repellent surface hydrophobic barrier. This property can be determined by measur-
ing the contact angle at the air–liquid–solid interface. Schematic depiction of the hy-
drophobic properties of the gastric mucosa under control conditions (A) (contact angle
readings between 60–80°) and after the stomach has been exposed to a luminal NSAID
and surface hydrophobicity is reduced (B) (contact angle readings <40°). SG, secretory
granule. Adopted from Lichtenberger et al., 2006, with a kind permission from John
Wiley and Sons.
1995). Furthermore, numerous studies have been performed to elucidate the nature of
NSAID-phospholipid interaction (Lopes et al., 2004; Marlene Lúcio et al., 2008; Moreno
et al., 2009; Panicker et al., 1995). It has been suggested, that the formation of isolated 1:1
drug–phospholipid-complexes with a preferential location at the polar head group, were
stabilized by cation-pi interaction, and seemed reasonable in organic solvents, whereas it
was found, that mainly liposomal and micellar structures were formed upon hydration
of the drug–phospholipid-complexes. Hence, the term “NSAID–phospholipid-complex”
could be misleading in the context of physiologically relevant aqueous media (Hüsch et
al., 2011).
Finally, the product, Aspertec
®
325 mg, based on the PLxGuard™ technology, has been
NDA-approved by the FDA. PLxGuard™ delivery system used phospholipids and free
fatty acids to modify the physicochemical properties of various drugs and to selectively
release these drugs to targeted portions of the GI tract. Unlike tablet or capsule poly-
mer coating technologies (e.g. enteric coating), which rely drug release on pH differ-
ences in the GI tract, the PLxGuard™ system used the differential in pH as well as bile
acid contents between the stomach and duodenum to target the release of the NSAID.
This approach was intended to release active pharmaceutical ingredients more reliably
in the duodenum and decrease their exposure to the stomach, which is more susceptible
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to NSAID-induced bleeding and ulceration (Cryer et al., 2011; Lanza et al., 2008; PLx
Pharma Inc., 2017).
1.2.2.3 Taste masking
The unpleasant taste of drug formulations attributed to the active ingredients or addi-
tives reduces the acceptance of several medications and hence may result in low patient
compliance.
Phosphatidic acid was successfullyused to mask bitter taste, as demonstrated by a study,
where an electronic taste sensor was developed in order to measure the masking effi-
ciency of the quinine (Nakamura et al., 2002). Furthermore, the selectivity of phospho-
lipids to mask only bitter flavours, while not affecting others, was established in a study
on volunteers, where soy lecithin, phosphatidic acid and phosphatidylinositol were used
(Katsuragi et al., 1997). Takagi et al. had similar findings, applying a cocktail com-
prised of 15–20% phosphatidic acid, 40% phosphatidyl inositol, 10–15% phosphatidyl
ethanolamine and 5% phosphatidylcholine in an electronic tongue device (Takagi et al.,
2001). Besides phosphatidic acid, hydrated PC can also be used to mask the taste of ac-
tive ingredients, as shown by Fini et al., who masked the taste of ibuprofen in tablets
(Fini et al., 2008).
1.2.2.4 Bioavailability enhancement
The increasing number of poorly water-soluble drug candidates in the pipelines of phar-
maceutical industry leads to emerging of the advanced drug delivery systems, which
would be able to increase their bioavailability. Many of these drugs, are class 2 drugs,
according to Biopharmaceutics Classification System (BCS) (low solubility, high perme-
ability). Consequently, the solubility and dissolution rates in the gastrointestinal tract
are the limiting steps for their absorption. Furthermore, BCS class 4 drugs (low solu-
bility, low permeability), also constitute substantial portion of drug candidates. Thus,
intestinal permeability is the rate limiting step, however, before these drugs still need to
dissolve.
There are two general principles to improve bioavailability of BCS 2 and 4 class drugs.
First, to increase dissolution rate and second, to deliver compounds already molecularly
dispersed in suitable solvent system. The first approach includes dosage systems, where
Chapter 1. Introduction 23
dissolution rate is enhanced either by increasing surface area (e.g. nanoparticle) or by
stabilizing an amorphous form of the drug in matrix (i.e. polymer, lipid etc.) (solid
dispersions). The second principle covers a wide number of systems, weher lipids and
surfactants are used to deliver drug in solution (i.e. oil solutions and emulsions to self-
emulsifying drug delivery systems).
There is a number of drug delivery systems implying phospholipids for drugs, that ex-
hibit poor water solubility (e.g. liposomes, mixed micelles, emulsions, self-emulsifying
drug delivery systems, solid lipid nanoparticles, suspensions, solid dispersions) (Fricker
et al., 2010).
Most of these delivery systems would result in liquid or semi-liquid systems, which re-
quire either solidification techniques for further processing into final dosage forms (Jan-
nin, Musakhanian, andMarchaud, 2008) by capsule filling and/or tableting (Bremmell et
al., 2013 or liquid filling into capsules (Savla et al., 2017). Additionally, these are complex
multicomponent systems, comprised of several lipid phase components and emulsifiers
(Pouton and Porter, 2008). There is quite extensive list of commercialized products (Table
4), however, very few of them actually contain phospholipids, which would mainly serve
as an oil phase constituents or co-emulsifiers.
As it appears from Table 4, there are few products on the market, that contain lecithin or
particular phospholipids, while majority contains digestible oils (i.e. soybean oil) and/or
surfactant systems.
Table 4. Commercially available Lipid-based products for oral administration.
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Trade name Molecule Therapeutic use Company Oils phase components
Marinol
®




































Saquinavir HIV antiviral Roche
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Rapamune
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Oleic acid, polyoxyl 35
castor oil
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emulsifier with a HLB <7
and an absorption
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contains progesterone (100 mg and 200 mg), which is used in combination
with estrogens mainly in hormone therapy for menopausal symptoms and low sex hor-
mone levels in women. Drug was micronized as a suspension in peanut oil, whereas
lecithin (approx. 0.4%) was used as a stabilizer, further the system is filled into soft cap-
sules.
Oral solution of ciprofloxacin (Cipro
®
) is indicated in numerous bacterial infections (uri-
nary tract infections; lower respiratory tract infections skin and skin structure infections
etc.) and was formulated to achieve flexible dosing for paediatric population as well as
to improve patient compliance among geriatric population. Ciprofloxacin, however, has
particularly unpleasant long-lasting bitter taste. Besides complete concealment of the
taste, a rapid and complete release of the active ingredient is unconditionally to be de-
manded, in order to guarantee bioavailability equivalent to the tablets. The successful
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taste-masking with simultaneously rapid and complete bioavailability of the active in-
gredient was achieved by microencapsulation of the active ingredient and further micro-
capsules redispersion in the oily digestible vehicle. Lecithin contained in the formulation
(approx. 0.5 to 5%) is one of the wetting agents used to increase the water tolerance of
an oily formulation and, on the other hand, facilitate the wettability of the microcapsules
during incorporation into the oily excipient liquid (US Patent US08191741).
Rapumine
®
is the only product so far, which contains phospholipids as a main solubiliz-
ing vehicle. It is an oral formulation of the immunosuppressant rapamycin, sirolimus
®
(marketed under the trade name Rapamune
®
by Pfizer), which is mainly used to prevent
rejection of kidney transplants. PHOSAL
®
50 PG is a standardized phosphatidylcholine
concentrate with at least 50% PC in propylene glycol, containing lecithin, sunflower
mono- and diglycerides and ascorbyl palmitate. The manufacturer of Rapamune
®
rec-
ommends to mix the dose with at least 60 ml of water or orange juice, but not any other
liquids, to stir the emulsion vigorously, to drink it immediately followed by another 120
ml of water or orange juice. A previous study investigated the impact of two different
formulations of Sirolimus
®
on blood levels and the development of arthritis induced in
rats (Carlson et al., 1998). On the one hand, Sirolimus
®
was formulated as a suspen-
sion with TWEEN™ 80 (Polysorbate 80) (polyethylene glycol sorbitan monooelate), and
on the other hand as a highly water-diluted emulsion containing PHOSAL
®
50 PG and
1% TWEEN™ 80. With all orally administered doses (0.5 mg/kg, 1.5 mg/kg and 4.5
mg/kg), the blood levels of the active ingredient were higher with the vehicle containing
phosphatidylcholine. These higher blood levels correlated positively with the therapeu-
tic effect on arthritic symptoms in the animals. With the PHOSAL
®
50 PG formulation,
approximately one-sixth of the dose proved sufficient to inhibit the arthritis, demonstrat-
ing that the application of phosphatidylcholine improved the absorption, effectiveness,
and therapeutic index of the active ingredient.
Solid dispersions of drugs in phospholipid matrix is another popular approach being ad-
dressed extensively in the research field. It is intended to “solubilize” crystalline drug in
phospholipid matrix, producing solid dispersions, with several points in mind. Namely,
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amorphization of poorly soluble crystalline drug would potentially increase its disso-
lution rate and extent. Further, it is believed, that once orally administrated diacyl-
phospholipids form liposome-like vesicles upon hydration, which further promote drug
dissolution rate due to increased surface area of colloidal suspension formed. Addition-
ally, as it was previsouy discussed, initiated digestion process of the liposomal phospho-
lipids, may increase the solubilizing capacity by forming endogenous mixed micelles.
The most recent and extensive review and meta-analysis prepared by Fong et al. com-
piled (Fong, Ibisogly, and Professor, 2015) 112 research articles and 82 patents, which
involved solid phospholipid-based formulations, out of which 54 articles and 13 patents
were described in detail (Figure 12).
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Figure 12. Summary of studies employing solid phospholipid-based formulations for oral drug
bioavailability enhancement in terms of (A) drugs being formulated; (B) the types of
study for evaluating their biopharmaceutical performance; (C) the lipid excipients em-
ployed; and (D) the process methods Adopted from Fong, Brandl, and Bauer-Brandl,
2015 with permission from Elsevier.
The summary from meta-analyses revealed that PL-based solid formulation produced
favourable biopharmaceutical enhancement effects on drugs. The highest enhancement
effect (in average) was found on drug solubility (2.27-fold), followed by permeability
(1.6-fold) and oral bioavailability (1.18-fold); whereas it has negligible effect on Cmax.
Furthermore, an optimization of the drug to lipid ratio and the selection of the most
suitable phospholipid for the formulation with drug in question should be performed.
Although, there were attempts made, to predict the technical feasibility of amorphous
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drug-phospholipid systems, with respect to degree of solubilization of the drug in the
dry and hydrated state (Fong et al., 2016, Fong, Ibisogly, and Professor, 2015, Gautschi,
Van Hoogevest, and Kuentz, 2015). So far, there was no systematic research published,
which compared saturated and unsaturated mono- and diacyl-phospholipids in order to
assess reasoned selection of phospholipid and its ratio to the drug. Moreover, the reli-
able and easy to apply screening methods are also still lacking in this field, as well as
stability data of phospholipid / drug solid dispersions. On the one hand, solid phospho-
lipid formulations have improved physical and chemical stability during storage, since
they can avoid the stability problems associated with the conventional liposomes such
as aggregation, susceptibility to hydrolysis and oxidation, while on the other hand, the
ability to maintain dispersed drug in amorphous state during long term storage, as well
as factors which would impact drug physical stability and formulation performance are
not reported in research literature.
1.2.2.5 Controlled release of lipid-based formulations
The term “lipid” describes a family of products with diverse physicochemical properties,
which includes oils, fats, waxes and fatty acids. Naturally occurring lipids are typically
triglycerides, esters of glycerol and three fatty acids (triacylglycerols). These glycerides
exhibit wide variety in acid chain length and saturation. In oral drug delivery, short chain
and unsaturated long chain fatty acids are widely adopted to effectively maintain the sol-
ubility and increase the bioavailability of poorly soluble drug compounds (discussed in
Section 2.2.2), while long chain saturated fatty acids are solid at ambient temperature and
water insoluble, showing potential for sustained release of water soluble drugs.
Over last decades naturally occurring triglycerides have been physicochemically modi-
fied to develop excipients suitable for the development of drug delivery systems (Fahy
et al., 2005). In contrast to polymers, solid lipids are crystalline in nature and do not ex-
hibit a glass transition (Tg) or minimum film forming temperature (MFT). Instead they
have reasonable melting ranges or melting points (approx. 45 to 85°C), which are deter-
mined by their chemical structure (and composition). The versatility of lipid excipients
has been successfully illustrated by the variety of processing techniques including cold
(compression) and hot (melt) processes.
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Table 5. Solid lipids used in sustained release drug delivery systems. Adopted from Rosiaux et
al., 2014 with permission from Elsevier.

















































































































Surprisingly, there were only few articles found using phospholipids, (i.e. hydrogenated
soy bean lecithin) compared to a vast number of reports with other lipids as it has been
extensively revised in literature (Table 5) (Feng and Zhang, 2017; Rosiaux et al., 2014).
Fujii et al. evaluated the release rates of acetaminophen from matrix tablets prepared by
direct compression as an effect of release medium pH and phospholipid species used as
a matrix former (Fujii et al., 1998). The direct relationship between the drug release rate
and matrix hydration rate was established, which was conditioned by the phospholipid
ionization state at different pH, and therefore should be taken into account when con-
trolled release formulations are intended with phospholipids.
Fini et al, reported that the ibuprofen release was delayed compared to pure ibuprofen,
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when was previously wet granulated with hydrogenated phosphatidylcholine powder
(Phospholipon
®
80H, PC content 60%, reported as lecithin). Ibuprofen and lecithin were
granulated at 4:1 weight ratio with water and compressed into fast dispersing tablets at
ca. 40% (w/w) content.
Another study also confirmed the controlled release potential of hydrogenated soybean
lecithin (Nishihata, Nakano, and Yamazaki, 1987). The sustained-release tablet of sodium
diclofenac (SR-tablet) was prepared compressing granules of sodiumdiclofenac and theo-
phylline with hydrogenated soya lecithin without any other additives. Granulation was
achieved by kneading drug and lecithin powders at 1:4 weight ratios with ethanol, fol-
lowed by drying. The dissolution of sodium diclofenac from the sustained release tablet
occurred in an apparent zero-order kinetics with 90% released at 24 hours. The human
subjects to whom the sustained release tablet was administered excreted diclofenac in
urine gradually up to 24 hours, while control formulation of diclofenac, was excreted
rapidly within 9 hours after administration. Similarly, extended release in vivo was con-
firmed for diclofenac sodium and theophylline in beagle dogs. The oral administration
of SR-tablets to dogs avoided a transient peak of drug concentration in the plasma and
maintained plasma drug concentrations at higher levels for a longer period, in compari-
son to the orally administrated theophylline suspension and commercial (immediate re-
lease) tablet of sodium diclofenac (Nishihata, Nakano, and Yamazaki, 1987).
The straightforward processing methods such as direct compression and wet granulation
are sometimes unsuitable for the formulation properties or the desired drug release pro-
file and, therefore, other techniques are applied.
Molding is one of the simplest and functionally effective ways to produce lipid-based
sustained drug delivery systems. The lipid excipient is completely melted and the drug
dispersed within the melt. The molten drug–lipid mass is directly filled into a casting
mold system allowing for different shapes and sizes. Chime et al. has reported the use of
hydrogenated phosphatidylcholine (Phospholipon
®
90H) in mixture with hydrogenated
palm oil (Softisan
®
154) at different weight ratios to prepared sustained release moulded
tablets of diclofenac sodium (Chime, 2013). The mixtures of phospholipid and hydro-
genated palm oil were prepared by fusion. In each case the lipids were weighed, melted
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together and stirred at a temperature of 70°C using a magnetic stirrer until a homoge-
nous, transparent white melt was obtained, further drug powder was dispersed in re-
sulting melt followed by filling into mould and solidification at room temperature.
The hot techniques are manifold and their use generally depends on the equipment avail-
able and the desired product application. The use of phospholipids, however is almost
inexistent, compared to the conventional and synthetic lipids (Table 6).
Melt granulation is rapid, single-step, solvent-free method, it can be advantageous for ex-
tended release formulations which require high drug loadings or use freely water-soluble
drugs. Generally, all ingredients are pre-blended in a high shear mixer before the temper-
ature is slowly increased to the lipid melting point. Due to subsequent (partial) fusion
of the lipid, particles bind together and build free flowing granules. Temperature is a
critical processing parameter and must be well controlled to avoid insufficient granula-
tion or ‘over wetting’ resulting in undesired particle agglutination. Using lipid excipients
as binder for solvent-free granulation facilitates drug bonding and reduces dosage form
wettability, which subsequently leads to slower drug release. This technique has the ad-
vantages of simplicity, high drug loading and the flexibility to produce different dosage
forms; however, the reproducibility of conventional melt granulation can be an issue due
to the inherent physicochemical properties of the lipid excipients.
Furthermore, an increasingly popular is hot melt extrusion (HME), a continuous produc-
tion process, which is reported to be straightforward to scale up. The combination of low
melt viscosity of certain lipid excipients and the shear forces developed during extrusion,
enable the processing of higher drug contents, whilst providing very homogeneous drug
in lipid dispersions (Feng and Zhang, 2017).
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Table 6. Examples of lipid excipient-based, sustained-release dosage forms prepared using twin-
screw extrusion process. Adopted from Feng and Zhang, 2017 with permission from
Springer Nature.
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Solid dosage forms made with insoluble lipid excipients were reported remaining intact
during drug release without gel formation or erosion of the dosage form/device. This
suggested pure Fickian diffusionmechanism, where: (i) water penetrated into the matrix,
(ii) dissolved the drug, (iii) occupied the pores generated by the diffusion of dissolved
drug particles and (iv) created water-filled channels which increased matrix porosity and
drug mobility, allowing for continuous drug diffusion out of the dosage form and into
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the release medium. Assuming, that this release mechanism is correct (i.e. that the lipid
matrix completely maintains its geometric form during dissolution and pure Fickian dif-
fusion is the underlying drug release mechanism) water diffusion into the device is an
important release rate controlling factor. Matrix wettability as well as initial air porosity
are hence a key factors, which mainly depend on the properties of the lipid and the drug,
as it has been demonstrated (Kreye et al., 2011b). According to the predominant diffu-
sion mechanism, the dosage form dimension should also affect drug release rates from
lipid matrices (Güres et al., 2012; Kreye et al., 2011a). Roberts et al. described the need to
increased lipid concentrations to obtain sustained release profiles from mini-tablets com-
pared to standard tablets (Roberts et al., 2012). Indeed, larger dimensions lead to longer
diffusion pathways (i.e. more time is needed to penetrate the matrix), which delayed
drug dissolution, pore creation and drug diffusion. However, it is believed that the effect
of device dimension on the entire drug release kinetics becomes minor with drugs being
extremely water-soluble (e.g. metformine HCl, bupropion HCl), which require very little
water to be completely dissolved and released. Therefore, dissolution and diffusion of
the drug after penetration of water into the device take place more rapidly compared to




• To characterize phospholipid materials in terms of processability into solid dosage
forms suitable for oral drug delivery
• To evaluate methods to process high amounts of phospholipids in the tablets, thus
allow to consider them as functional excipients to serve variety of needs
• To evaluate the general applicability of hydrogenated phosphatidylcholine as a re-
lease retarding matrix-former for direct compression and to establish clear cause-
effect relationships between formulation parameters and drug release rate
• To understand the mechanism of pH- dependent behaviour of phosphatidylcholine
powder and to explore methods to minimize or disguise it in drug formulations
• To evaluate the feasibility of processing hydrogenated phosphatidylcholine by hot
melt extrusion and to explore release rate controlling potential of resulting matrices
with special attention to high loadings of water-soluble model drugs
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3 Results and Discussion
3.1 Characterization of Rheological Properties of Phospholipid
Powders and Evaluation of Their Processability into Solid
Oral Dosage Forms
3.1.1 Background
Phospholipids (PL) have become attractive candidates as carriers for oral formulations
during the last years, due to their physiological role in absorption processes and physico-
chemical diversity, capacity to enhance oral bioavailability of poorly water-soluble drugs,
their favorable biocompatibility and lack of toxicity (Fong, Brandl, and Bauer-Brandl,
2015).
A number of described lipid based systems, (pro)liposomes, oils, emulsions, self-emulsify-
ing drug delivery systems (SEDDS), solid lipid nanoparticles, suspensions and solid dis-
persions (Fricker et al., 2010) requires capsule filling for successful oral delivery, which
could be technologically challenging. Tablets, on the other hand, are the most popular
and preferred oral dosage forms in terms of precision of unit dose, low cost, patient com-
pliance, and good physical and chemical stability. There are, however, just few studies,
which have evaluated conventional dosage forms such as tablets containing phospho-
lipids. In the reported studies, phospholipids were used as gastric mucosa protector in
administration with NSAIDs (Anand et al., 1999; Dial et al., 2008), taste masking agent
(Fini et al., 2008; Katsuragi et al., 1997) and drug release retarding agent (Chime, 2013;
Fini et al., 2008; Raffin et al., 2009). Phospholipids have been wet granulated with model
drugs and their effect on studied parameters has been determined, however, general ef-
fects on tablet processing have not been addressed. It is, therefore, of an interest to evalu-
ate the processability of phospholipids in tablets, irrespective of whether solubilisation /
bioavailability enhancement of insoluble drugs or the controlled release of soluble drugs
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at higher loadings is in focus.
Powder flow and hygroscopicity were identified as essential material properties to assess
its general applicability for tableting and to define suitable methods for its processability
(Banker and Rhodes, 1990).
Uniform weight of tablets is achieved by feeding constant volumes of homogeneous ma-
terials to the dies of the tableting press. Therefore, to avoid material segregation during
mixing and feeding, excipients should possess comparable particle size and bulk densi-
ties, hence material powder characteristics would strongly influence the choice of tablet-
ing methods (e.g. direct compression, wet and/or dry granulation).
Additionally, moisture content present in the material during manufacture, as well as
that in the final product contributes to the behaviour of many tablet formulations, in ad-
dition to its potentially adverse effect on stability. Therefore, the material behaviour at
different relative humidity levels is essential knowledge for choosing strategies for its
further processing.
The aim of this workwas, thus, to characterise phospholipid powders in terms of process-
ability to solid dosage forms suitable for oral drug delivery and to evaluate the methods
to achieve high amounts of phospholipids in the tablets, thus allow to consider them as
functional excipients to serve variety of needs.
3.1.2 Materials and Methods
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SMCC (JRS PHARMA GmbH
& Co. KG, Rosenberg, Germany); Aeroperl
®
300 pharma (Evonik Industries AG, Essen,
Germany); Neusilin
®
US2 (Fuji Chemical Industries Co., Ltd., Japan).
3.1.2.1 Powder flowability
Powder flow properties were assessed with Compressibility Index (Carr’s Index) (CI)
and Hausner Ratio (HR) measurement. Both were determined according to the method
outlined in the USP (Entry 1174). Samples (50-75 g) were passed into a pre-weighed
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250 ml graduated cylinder with 2 ml markings. The bulk volume (V0) was measured
after gently shaking the cylinder few times to achieve leveled filling. The tapped volume
(Vt) was measured with the Erweka Tap Density Tester (Erweka GmbH, Heusenstamm,
Germany) after tapping 1250 taps. Bulk and tapped densities were used to calculate









where, ρtapped is the tapped density and ρbulk is the bulk density
3.1.2.2 Characterisation of phospholipids solid state by X-ray diffraction (XRD)
Samples as received were analysed by X-ray diffraction using a Philips X-ray generator
PW 1830 (Philips Industrial and Electroacoustic Systems Division, Netherlands) with a
diffraction angle range between 4° and 40° 2Θ and a step size of 0.02° 2Θ.
3.1.2.3 Powder hygroscopicity: Dynamic Vapor Sorption (DVS)
The moisture uptake studies were performed with a DVS instrument (DVS 1000, Surface
Measurement Systems Ltd., UK) at 25±0.1°C. The instrument consisted of a microbal-
ance housed inside a temperature-controlled chamber. The humidity was controlled via
switching valves, which control the flow of a dry gas (nitrogen) through a humidification
stage. Samples (10±2 mg) were loaded onto a tared sample pan and an empty pan was
used as the reference. The samples were dried at 25°C/0% RH for 180 min and the in-
strument was programmed for moisture sorption from 0 to 98% RH in 14% RH steps for
90 H; 80 H; 90 G; S 75; S 45 and S LPC 80 and from 0 to 87.5% RH in 12.5% RH steps and
10.5% step till 98% RH for R LPC 20 at 25±0.1°C, at equilibrium condition. The equilib-
rium condition was set to <0.05% total mass change within 5 min and with a maximum
dwell time of 180 min.
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Isotherms were calculated using the DVS Advanced Analysis Suite from the complete
sorption and desorption profiles. Sorption and desorption rates of different PL were
compared by converting polynomial sorption profiles into linear function and compar-
ing resulting slopes’ values.
3.1.2.4 Wet granulation
Pestle and mortar was used for wet granulation. Combination of microcrystalline cellu-
lose (MCC) (Avicel
®
101) and lactose (GranuLac
®
200) at the 1:3 ratio was used as fillers
for granulation. Ethanol 96% (v/v) was used as a granulating fluid. Wet mass was passed
through 800 µm sieve, resulted granules were dried in ventilated oven at 40°C overnight.
Batches of ca. 10 g were produced.
3.1.2.5 Direct compression
Phospholipid powders (as received) were blended with additional excipients for 10 min
in a Turbula mixer (Willy A. Bachofen AG, Basel, Switzerland), then, 1% w/w magne-
sium stearate was added and further mixed for 3 min.
3.1.2.6 Tableting
Flat-faced, 8 mm diameter, tablets were compressed using single punch tablet press (Ko-
rsch EKO, Korsch Pressen GmbH, Berlin, Germany). The tablets were characterized for
their dimensions and hardness (Multicheck, Erweka GmbH, Heusenstamm, Germany).
Disintegration time was determined by PharmaTest Dist-3 (Pharma Test Apparatebau
AG, Hainburg, Germany) in 0.1N HCl at 37°C.
3.1.2.7 Phospholipids adsorption onto carrier
Phospholipids were dissolved in warm ethanol (50°C) at the 50% w/v and added to a
carrier under continuous mixing in a Mixer Torque Rheometer (Caleva Process Solutions
Ltd. Dorset, England) at different lipid to carrier ratios. The resulted wetted powder or
past-like mass was dried in the ventilated oven at 40°C overnight and once dry, sieved if
needed.
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3.1.3 Results and Discussion
3.1.3.1 Physical characterization and rheological properties of PL powders
Grades of phospholipid differing in purity, side chains and saturation were evaluated
(Table 7). Unsaturated phospholipids presented as coarse agglomerates ranging from
brown-yellow to pale yellow color as a function of phosphatidylcholine (PC) content,
while saturated phospholipids were fine white powders.
Table 7. Summary on appearance and composition of studied phospholipid powders.
































min. 45% PC*, 10% PE,
max. 4%
MA-PC***, brown agglomertes
*PC – Phosphatidylcholine; **PE – Phosphatidylethanolamine;
**MA-PC – Monoacyl-phosphatidylcholine
The solid state of phospholipid powders was determined with X-ray diffractometer. Ac-
cording to XRD, phospholipidswith fully saturated fatty acid chains, as well asmonoacyl-
PL LPC 80 had crystalline and semi-crystalline structure, while unsaturated 90 G, S 45, S
75 and monoacyl-PL R LPC 20 were amorphous (Figure 13).
Powder flow properties
Powder flow properties of saturated phospholipids, 90 H and 80 H, were assessed with
compressibility index and Hausner ratio (Table 8). According to USP provided refer-
ence table (Table 9) 90 H presented good flow properties suitable for direct compression,
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Figure 13. X-ray diffractogram of studied phospholipids (up to down): 80 H; 90 H; LPC 80; S 75;
S 45; 90 G; R LPC 20.
whereas 80 H had very poor powder flow capacity. Further laser diffraction particle size
analysis of powders revealed that 80 H had fraction with finer particles, which could be
responsible for its higher cohesiveness and thus poor flow.
Table 8. Compressibility index and Hausner ratio of saturated phospholipids.






80 H 0.335±0.005 0.496±0.027 32.45±2.804 1.468±0.060
90 H 0.567±0.002 0.65±0.008 12.64±1.207 1.154±0.016
Table 9. Scale of flowability.
Compressibility Flow Hausner Compressibility Flow Hausner
index (%) character ratio of index (%) character ratio
≤10 excellent 1.00 -1.11 21-25 passable 1.26 - 1.34
11-15 good 1.12 - 1.18 26-31 poor 1.35 - 1.45
16-20 fair passable 1.19 - 1.25 32-37 very poor 1.46 - 1.59
Moisture uptake by phospholipids
Dynamic vapor sorption study was performed with all phospholipid samples, in order
to obtain equilibrium moisture content (EMC) at different relative humidity (RH) lev-
els. Furthermore, the sorption and desorption rates of different phospholipids have been
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calculated and compared. Equilibrium moisture content at 45% RH was 5.38 and 7.41%
for 80H and 90 H, respectively, elevating to 9.30 and 11.00% at 75% RH, and reaching
maximum of 24.11% and 20.22 at 98% RH (Figure 14 A and 14 B).
Figure 14. Isotherm plots of studied phospholipids.
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Unsaturated phospholipids S 45, S 75, and 90 G at 45% RH had equilibriummoisture con-
tent 4.78, 6.04, and 7.94%, respectively, which was comparable the ones of saturated 90 H
and 80H. Further, at RH of 75% these substances reached 17-20% EMC and finally 30-35%
at 98% RH (Figure 14 C, D and E). Moreover, isotherms of unsaturated diacyl-PL, S 45, S
75 and 90 G presented open hysteresis loop, hence moisture did not desorb completely
even after drying at 0% RH, indicating moisture-induced phase transition, which was
in agreement with the observation, that even small amount of absorbed humidity from
the environment (e.g. exposure to open air for 1-2 hours) induced visible irreversible
morphological changes, converting these phospholipids into paste like substances. Un-
saturated monoacyl-PL S LPC 80 and R LPC 20, presented as the most hygroscopic sub-
stances. The highest EMC at all RH levels, as well as fastest moisture sorption rate were
observed for S LPC 80 (Figure 14 C), however it did not turn into semi-solid paste at
room conditions as the other unsaturated PL did. The equilibrium moisture contents for
different phospholipids at relative humidity levels of 45, 75 and 98% were summarized
in Figure 15.
Figure 15. Equilibrium moisture content of phospholipid samples at 45, 75 and 98% relative hu-
midity levels.
In order to estimate how fast moisture uptake occurred, sorption rates have been calcu-
lated and compared. First, the relative moisture uptake curves for each humidity step
were linearized by applying square roots of time, thus slopes of the resulting linear re-
gression corresponded to the rate of moisture uptake, and were further plotted against
corresponding relative humidity values (Figure 16). All studied phospholipids had simi-
lar constant sorption rate over wide range of humidity levels, from 14 to 84%, and finally
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Figure 16. Sorption and desorption rate profiles for (A) saturated Phospholipon 90 H; (B) unsat-
urated Phospholipon 90 G and (C) monoacyl- Lipoid S LPC 80.
increased rate, corresponding to the RH step from 84 to 98%. Desorption rates were
similar to sorption over the whole range of relative humidity levels for saturated PL.
On the other hand, for unsaturated PL desorption was faster than sorption at RH 98 to
75%, which corresponded to elimination of bulk water, and then slower at lower relative
humidity levels, indicating the difficulty to remove moisture (Figure 16 B), which was
in accordance with open hysteresis loop previously observed on the moisture isotherm.
Especially remarkable difference was observed for S LPC 80, indicating its hygroscopic
nature (Figure 16 C).
According to classification proposed by J.C Callahan (Callahan et al., 1982) samples could
be divided into 4 groups according to their equilibrium moisture content. Overall, mois-
ture sorption study showed, that saturated phospholipids could be considered as slightly
hygroscopic substances with low constant moisture sorption rate over the wide range of
relative humidity levels. Unsaturated phospholipids could be classified as moderately
Chapter 3. Results and Discussion 46
hygroscopic substances, the moisture uptake at 25°C had low constant rate over wide
range of RH, however even amount of moisture adsorbed from the air within few hours
on the bench, produced visible morphological changes, converted phospholipid aggre-
gates into semisolid mass. Special packaging and storing conditions were needed for
these materials (refrigeration, desiccator chambers and aluminium sacs). Unsaturated S
LPC 80 had the highest equilibrium moisture content, and could be considered as highly
hygroscopic material, however no visible morphological changes were observed upon
moisture uptake. Further treatments should be considered to convert unsaturated phos-
pholipids into flowing powders (e.g. wet granulation), while moisture should be avoided
in the manufacture processes, as well as the room humidity and temperature should be
controlled.
3.1.3.2 Tabletability of phospholipids (placebo study)
Taking into account, that potential solubility enhancing effect by phospholipid disper-
sions was generally achieved at low drug to lipid ratios, significant phospholipid content
should be formulated into solid dosage forms. Therefore, the main goal of this study
was to evaluate processability of high PL content by the means of compression. Thus,
powders compactability and tablets disintegration times were identified as challenging
parameters for immediate release dosage forms formulation, due to stiff and un-porous
nature of material, and therefore, were further studied and optimized. As it was sug-
gested in the previous section, direct compression approach was merely feasible for sat-
urated phospholipid 90 H powder in terms of powder density and flow, while for un-
saturated phospholipids wet granulation feasibility was explored. Additionally, phos-
pholipid adsorption onto porous carrier was performed in order to increase processable
phospholipid amount for tableting. Three different carriers have been studied: silicified
microcrystalline cellulose (Prosolv
®






Direct compression: Phospholipon 90 H
Phospholipon 90 H powder, as received, was blended with 0.5% of magnesium stearate
and compressed on single punch press. Resulted 8 mm diameter tablets had relatively
low tensile strength, which was independent of compression force and plateaued at
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0.85 N/mm
2
. 90 H placebo tablets resulted in insoluble matrix, which did not disinte-
grate after at least two hours of disintegration test. The use of common tablet excipi-
ents with Phospholipon 90 H was investigated for an effect on blend compactability and
tablets disintegration time. Tablets with high loadings of 90 H powder (50 and 70%)
were formulated with addition of microcrystalline cellulose (MCC) and additional dis-
integrant, croscarmellose sodium, and compared to formulations with ready-to-use di-
rect compression excipient, Ludipress
®
, which combines lactose monohydrate as a filler,
polyvinylpyrrolidone (PVP, Kolidon 30
®
) as a binder and crosslinked PVP (Kolidon CL
®
)
as a disintegrant (Table 10).
Table 10. Tablet formulations for direct compression with 90 H.
Batch A Batch B Batch C Batch D
90 H 50 70 50 70
Avicel
®
102 40 20 - -
Ac-Di-Sol
®
9.5 9.5 - -
Ludipress
®
- - 49.5 29.5
MgSt 0.5 0.5 0.5 0.5
Overall, all blends had a good processability and adequate flow for direct compression.
The combination of MCC and additional disintegrant (Batches A and B) was superior in
terms of tablet hardness and had shorter disintegration time (Figure 17).
However, disintegration time at 37°C, with high loadings of saturated phospholipids was
generally longer than 15minutes, indicating 90H suitability as amatrix forming excipient
for extended release dosage forms, rather than immediate release formulations.
Figure 17. Effect of 90 H content in tablets with different formulation on (A) compactability and
(B) disintegration time.
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Wet granulation feasibility
As it was found in the moisture sorption study even small amount of water added to un-
saturated phospholipids converted them irreversibly into sticky semi-solid mass, which
was also in accordance with results published by Fini and co-workers regarding wet
granulation, where it was stated that, agglomerates formed with Lipoid S 75, had rubber
consistency, did not dry, but remained as a soft paste and were unsuitable for further pro-
cesses (Fini et al., 2008). To avoid moisture, ethanol 96% (v/v) was used as a granulating
fluid. Unsaturated phospholipids were soluble in ethanol at a room temperature, hence
formation of solid bridges necessary for a successful granulation was expected and no
additional binders were added to the formulation, in order not to compromise further
the disintegration time.
Powders as received were not processable on their own, therefore microcrystalline cel-
lulose and lactose (1:3 w/w ratio) were added as diluents. Unsaturated PL could be
granulated at the maximum content of 30% by weight, resulting in very soft granules,
which were further blended with 1% Aerosil
®
in order prevent them from agglomer-
ating. Furthermore, granules containing 30% of unsaturated phospholipids were, not
directly processable into tablets due to punch sticking. Thus, PL content was reduced
to 15, 10 and 5% in a granule (further referred as Method A) and then successfully com-
pressed into tablets. For comparison, granules with 30% PL content were mixed with
additional diluent granules (MCC:lactose ) and were compressed into tablets with total
phospholipids content of 15, 10 and 5% (further referred as Method B). Extra-granule dis-
integrant, croscarmellose sodium (Ac-Di-Sol
®
), and lubricant, magnesium stearate, were
added prior to compression (Table 11).
All unsaturated phospholipids had very similar compactability profiles. Figure 18 A
Table 11. Phospholipid tablets formulations prepared by wet granulation.
Method A Method B
phospholipids content in tablet 5% 10% 15% 5% 10% 15%
phospholipids content in granule 5% 10% 15% 30% 30% 30%
PL: MCC:Lac granules 90% 90% 90% 16.67% 33.33% 50%
MCC:Lac granules - - - 73.33% 56.67% 50%
Ac-Di-Sol
® 9.5% 9.5% 9.5% 9.5% 9.5% 9.5%
MgSt 0.5% 0.5% 0.5% 0.5% 0.5% 0.5%
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presents effect of 90 G content in resulting tablets on their tensile strength and disinte-
gration time. At low PL content tablets had increasing tensile strength with increasing
compression force; effect was more pronounced on tablets formulated by Method A, due
to more homogeneous distribution of diluents in the tablets. At 15% phospholipid con-
tent tablet tensile strengthwas low and independent of compression force. It was hypoth-
esized that due to low-porous nature of the material, tablets porosity was at its minimum
already at the 5 kN compression force, and further increase in force did not contribute to
interparticle bonding and hence no increase in tablets tensile strength was observed. On
the other hand, addition of diluent granules (Method B) into tablet formulation improved
disintegration time (Figure 18 B).
Overall, wet granulation with ethanol 96% (v/v) was feasible process for tableting of un-
saturated and monoacyl- phospholipids. Up to a 30% PL content could be processed,
resulting, however, in soft granules, which were not directly processable into the tablets.
Tablets with maximum phospholipid loadings of 15% could be achieved by means of
wet granulation method. Faster disintegration time could be achieved by adding diluent
granules. Sticking to the tablet punch was a major issue when compressing phospho-
lipids at all contents.
Figure 18. Effect of 90 G content on (A) compactability and (B) disintegration time in tablets.
Further steps should be considered to minimize it by using brittle porous diluents ma-
terials such as sugars, dicalcium phosphate, addition of antiadherents and glidants like
colloidal silicates.
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Adsorption onto porous carrier
Adsorption onto porous carrier was performed in order to increase maximum process-
able content of unsaturated phospholipids in a tablet. Two groups of carriers have been
studied: common tableting excipient – microcrystalline cellulose, and highly porous ma-




SMCC 90LM is combination of microcrystalline cellulose (MCC) and colloidal
silicon dioxide, which results in a five-fold specific surface area increase and 30-50% com-
paction increase compared to traditional MCC. (JRS Pharma brochure). Powders with the
different PL to Prosolv
®
ratios (w/w) have been studied (Table 12).










Final PL content in
powder, %
1 5 1:5 20 16.7
1 2.5 2:5 40 28.6
1 1.67 3:5 60 37.5
1 1.25 4:5 80 44.4
1 1 1 100 50
Resulting powders presented as coarse granule-like particles and according to USP spec-
ifications (Table 9) had a good flow (Figure 19). Starting from phospholipids to Prosolv
®
loadings of 80%, carrier surface started to get saturated with phospholipids and resulted
in increasingly sticking powder. Blending with 1% of Aerosil
®
helped to reduce the stick-
iness.
For tableting, powders with different loadings of phospholipids to Prosolv
®
(Table 12)
were blended with 0.5% magnesium stearate and compressed at 5, 10, 15, 20 kN com-
pression force (Figure 20). Unsaturated phospholipids had similar compactability pro-
files at all loadings. S LPC 80 generally formed slightly harder tablets, probably due to
its more crystalline nature than other unsaturated phospholipids. With increasing phos-
pholipid content, tablets hardness decreased, independently of PL grade. When more
than a 60% phospholipids loading was used, the tablet hardness was independent of the
compression force applied, due to high content of soft un-porous material.
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Figure 19. Compressibility index of phospholipids Prosolv
®
powders at different phospholipid
loadings.
To determine the disintegration time 90 G: Prosolv
®
1:1 powder was blended with 9.5%
AcDiSol
®
and 0.5%magnesium stearate and compressed at 8-10 kN into flat 8mm tablets.




powders had good flow properties and the resulting
tablets had an acceptable hardness over the range of studied loading ratios. However,
due to long disintegration times, these powders could be rather considered as excipients
for extended release formulations. Taking into consideration, that tablets hardness was
independent of compression force at high phospholipids loadings, low compression force






are highly porous carriers, with specific area of ca. 300 m
2
/g
and particle size below 100 µm. Both powders had improved bulk density and flow,
suitable for processing and direct compression. Ethanolic solutions of phospholipid were
adsorbed onto these carriers at the phospholipid to carrier ratios (w/w) of 1:1 and 1.5:1
(Table 13).
Table 13. Phospholipid content in Aeroperl- and Neusilin-based powders.
PL, g Carrier, g
PL to carrier w/w
ratio
Final PL content in
powder, %
1 1 1:1 50
1.5 1 3:2 60
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Figure 20. Compactability profiles of phospholipid-Prosolv
®
powders. (A) 90 G; (B) S 75; (C) S
45; (D) LPC 80.
Resulting powders presented as fine granule-like particles and had a good to excellent
flow (Figure 21).
For tableting, the resulted powders were blended with 0.5% magnesium stearate and
compressed at 5, 10, 15, 20 kN compression force.
Aeroperl- andNeusilin-based phospholipid powders had similar compactability profiles,
almost independent of compression force applied. Neuslin-based phospholipid pow-
ders formed slightly harder tablets than Aeroperl-based tablets. For disintegration test,
adsorbed powders were mixed with 9.5% croscarmellose sodium (AcDiSol
®
) and com-
pressed at 8-10 kN compression force. Aeroperl-based tablets resulted in faster disinte-
gration times, permitting to achieve 45% PL loading in the tablet with reasonable disin-
tegration times (5-10 minutes) (Figure 22).
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Figure 21. Compressibility index of Aeroperl- and Neusilin-based PL powders.
Figure 22. Effect of highly porous carrier type on (A) compactability of 1:1 phospholipid: carrier
blends and (B) disintegration time of tablets with 45% phospholipid content.
Up-scaled process for Aeroperl-based phospholipid powders
Adsorption of unsaturated phospholipids onto highly porous carriers, resulted in flow-
ing, well compactible blends with high phospholipid loadings. To evaluate feasibility to
apply this method at a bigger production scale, batches of 250 g were prepared for 90 G




Chopper speed: 450-300 rpm
90 G/S 45 ethanol solution: 50-60% (w/w)
Spraying nozzle: 4/30°
Pump speed: 16 g/min
Wet powder was dried for 24 hours in vacuum oven at room temperature. Resulted dried
compacts were sieved through 500µm sieve by Frewitt GLA-ORV Labaratory oscillating
Granulator.
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General recommendations
• Phospholipid ethanol solution should be at least 50% w/w in order to reach 1.5:1
loading (60% PL content): 100 g of carrier can adsorb ca 300 ml volume. At 50%
w/w PL concentration, it results in 100 g carrier to 150 g PL
• Use a Moderate mixing speed, high shear should not be applied; ca 450 rpm till
reaching 1:1 carrier: phospholipid ratio, later slow down to 300 rpm to ensure uni-
form wetting of the carrier without forming compacts
• Ensure uniform distribution of phospholipid ethanolic solution, a fine nozzle with
moderate pump speed is preferred Ensure that the residual moisture content after
drying is not more than 3%, otherwise sieving can be compromised
• Do not use a small sieve pore size (<500 µm) at the first step of sieving; at high
friction phospholipids may form solid film on the sieve, making the further sieving
impossible
Powder residual moisture was determined after powder drying for 24 hours in vacuum
oven by loss on drying method and was 1.61 and 1.79% for 90 G and S 45, respectively.
To respond to the concerns regarding resulted powder hygroscopicity and thus long-
term stability, due to significantly increased surface area (PL aggregates vs. fine pow-
der), moisture content was measured in initial unprocessed phospholipid powder and
Aeroperl-based powder after 24 hours and 3 months of storage in bottles closed with a
screw lid at room conditions (RH 40%; 23°C) (Table 14).
Table 14. Moisture content in S 45 powder and Aeroperl-based S 45.
Moisture content, %
Powder




S 45 1.4±0.071 4.815±0.064
Aeroperl-based S 45 powder, had no increase in moisture content through out the storage
period, while unprocessed S 45 presented 3 folds moisture content increase. Therefore,
the additional excipients to convert PL aggregates into free-flowing powders have had
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positive impact on equilibriummoisture content at room conditions. Additionally no vis-
ible changes neither in morphology nor in rheological behavior of the resulted powders
were observed (Figure 23).
Figure 23. S 45 untreated material (left) and Aeroperl-based S 45 powder (60% PL content) (right)
after 3 months storing at room conditions. S 45 converted into semi-solid paste, while
Aeroperl-based S 45 remained freely-flowing powder with no visible morphological
changes.
3.1.4 Conclusions
Overall, phospholipids could be processed into solid oral dosage forms (e.g. tablets)
by different methods: direct compression (saturated phospholipids), wet granulation
and adsorption onto carrier (unsaturated phospholipids). Main limiting factors for wet
granulation were stickiness of the materials (unprocessable mass) and resulting tablets
softness. Sticking to the tableting machine punch could partly be managed by addi-
tion of 1% of colloidal silica, as well as the use of brittle materials as additional tablet-
ing/granulation excipients increasing tablets hardness. The phospholipid content af-
fected disintegration time and tablets hardness. Although, resulting tablets tensile strength
was not very high, due to very low friability, even at high phospholipid content, tablets
could withstand further processing, whereas, the disintegration time could be managed
by additional excipients (disintegrants, and diluents). Free flowing powders with a high
phospholipid content could be produced by using adsorbents. Main factors that lim-
ited the phospholipid content in the powder are the carrier adsorption capacity and the
phospholipid solubility in ethanol. The method could be easily scaled up using common
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pharmaceutical lab/production equipment. Tablets with up to 60% of unsaturated phos-
pholipids content could be achieved by this method. Disintegration time, was the most
affected parameter with increased phospholipids content, could be reduced by adding
intra- and extra granular disintegrants, and diluent excipients. Table 15 summarizes the
previously discussed methods and achieved phospholipids contents.
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up to 15 minutes DT
- Adjust PL content
- Add intra- /extra granular
disintegrant
- Add diluent granules
- 70% saturated PL
content + 9.5% disintegrant
resulted in
20 minutes DT




- Adjust PL content
- Add extragranular
disintegrant
- Add diluent excipients




results in up to
15 minutes DT
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3.2 Saturated Phosphatidylcholine asMatrix Former for Oral Ex-
tended Release Dosage Forms
1
Abstract
The aim of this study was to evaluate the suitability of saturated phosphatidylcholine
(Phospholipon
®
90H) as extended release excipient in matrix tablets for three model
drugs with different aqueous solubility (theophylline, caffeine and diprophylline). The
tablets could be prepared by direct compression because of the favourable phospholipid
powder flow properties (Carr’s index: 12.64 and angle of repose: 28.85) and good com-
pactibility. Tablets of low porosity were formed already at low pressure of 40 MPa and
with drug loadings up to 70% due to high plasticity of the phospholipid. Extended drug
release was achieved with the drugs of different solubility and at various drug loadings.
For example, the caffeine release time t80 from 8 mm tablets ranged from 1.5 h to 18 h
at 70% and 10% drug loading, respectively. The drug release was governed by diffusion
and could therefore be modelled by Fick’s law of diffusion. Drug release profiles were
thus a function of drug solubility, drug loading and tablet dimension. Matrix tablets of
caffeine (20% drug loading) showed robust dissolution with regard to agitation (50–100
rpm) and ionic strength of the release media (100–600 mOsmol/kg). Caffeine release
was pH-dependent with a faster drug release at acidic pH, which was attributed to a pro-
tonization of the phosphatidyl group of the matrix-former and thus a higher hydrophilic-
ity.
Keywords
Phosphatidylcholine; Phospholipids; Direct compression; Extended release; Matrix tablet
1
Kolbina, M., Bodmeier, R., Korber, M., 2017. Saturated phosphatidylcholine as matrix former for oral
extended release dosage forms. Eur. J. Pharm. Sci. 108, 86-92. doi:10.1016/j.ejps.2017.07.017
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3.2.1 Introduction
Phospholipids are isolated from natural sources like egg, soybean, rapeseed, and sun-
flower seed. The most common phospholipid is phosphatidylcholine, which is also the
most abundant component of lecithin. Normally, lecithin grades containing more than
80% phosphatidylcholine are called arbitrarily phosphatidylcholine, whereas grades con-
taining less than 80% phosphatidylcholine can be arbitrarily called lecithin (Hoogevest
and Wendel, 2014). Structurally, phospholipids comprise a glycerol backbone, which is
esterified in positions 1 and 2 with fatty acids and in position 3 with phosphate and other
functional groups. The length and degree of saturation of fatty acids chains as well the
variation of functional groups, leads to the existence of a wide variety of phospholipids.
Phospholipids have become attractive candidates as carriers for oral formulations dur-
ing the last years, due to their favorable biocompatibility, biodegradability and diversity
(Chakraborty et al., 2009).
Phospholipids have been used in two major applications in drug delivery. Firstly, their
solubility- and bioavailability-enhancing properties for poorly water-soluble drugs have
been investigated for several decades. Several lipid-based drug delivery systems have
been developed, which make use of their amphiphilic nature and the ability to form
vesicular structures in aqueous environments (Fricker et al., 2010). In addition, phospho-
lipids have been studied in extended release drug delivery systems to some extent. Ac-
etaminophen tablets were prepared by direct compression with different hydrogenated
phospholipids rich in phosphatidylcholine, phosphatidylethanolamine and phosphatidyli-
nositol fractions in order to determine effect of phospholipid species and pH on drug
release (Fujii et al., 1998). Orally disintegrating ibuprofen tablets with controlled re-
lease were formulated (Fini et al., 2008). Granules of ibuprofen and hydrogenated phos-
phatidylcholine at 4:1 weight ratio prepared by wet granulation showed a slower drug
release compared to pure drug granules. In another study, unsaturated lecithin (Lipoid S
45) was used as a binder to form soft agglomerates of gastro-resistant pantoprazole mi-
croparticles for an oral, delayed release dosage form (Raffin et al., 2009). Likewise, soy
phosphatidylcholines have been used for extended release tablets prepared by wet gran-
ulation or compression moulding of drug-phospholipid blends (Chime, 2013; Nishihata,
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Nakano, and Yamazaki, 1987). Phospholipids have also been studied as potential protec-
tants of the gastric mucosa in combination with non-steroidal anti-inflammatory drugs
(Anand et al., 1999; Dial et al., 2008), as well as potential taste masking agents (Katsuragi
et al., 1997).
Direct compression is usually preferred for tablet manufacture due to its simplicity and
cost-effectiveness. This approach has been successfully applied to synthetic or semi-
synthetic polymers such as Kollidon
®
SR (polyvinyl acetate-based), Eudragit
®
RS (poly-
methacrylate derivatives) or ethyl cellulose (Boza et al., 1999; Crowley et al., 2004; Grund
et al., 2014; Kranz, Brun, and Wagner, 2005). Potential matrix-formers of natural origin,
with regulatory acceptance and the feasibility to control the drug release from a blend
matrix are rare (e.g. carnauba wax, bees wax and shellac). In contrast to other natural
waxes such as carnauba or bees wax, saturated phosphatidylcholines could be an inter-
esting alternative as tableting excipients due to their natural origin, proven safety (GRAS
listed compound) and biocompatibility as well as a reproducible quality, high melting
temperature and their availability in fine powder form (Hoogevest and Wendel, 2014).
In this study, saturated phosphatidylcholine, composed of stearic and palmitic acids and
manufactured by hydrogenation of unsaturated phospholipids and chemically identi-
cal to the fraction of saturated phosphatidylcholines naturally contained in lecithin, was
evaluated as matrix former for extended drug release due to its insoluble nature in aque-
ous medium (solubility of dipalmitoyl phosphatidylcholine: 0.3 ng/ml; (Smith and Tan-
ford, 1972). The drug release from insoluble matrices is predominantly governed by
diffusion (Grund, Körber, and Bodmeier, 2013; Kreye, Siepmann, and Siepmann, 2008).
Therefore, a number of formulation factors which affect the drug diffusivity (i.e. drug
loading, matrix former particle size, tablet porosity, etc.), and hence the drug release rate,
were studied. Diprophylline, caffeine and theophylline, with corresponding aqueous sol-
ubilities (at 25°C) of 330, 20 and 8mg/mL ()(Remington andGennaro, 1990), were used as
model drugs. Direct compression of binary blends of drug and phospholipid was used in
order to establish clear cause-effect relationships and to evaluate the general applicability
of this excipient as release retarding matrix-former.
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3.2.2 Materials and Methods
3.2.2.1 Materials
Saturated phosphatidylcholine of stearic and palmitic acid (Phospholipon
®
90H, Lipoid
GmbH, Ludwigshafen, Germany), caffeine anhydrous fine powder, theophylline anhy-
drousmicronized powder, diprophylline (BASF SE, Ludwigshafen, Germany); TLC plates
silicagel 60, β-(N-Morpholino)ethanesulfonic acid (MES) monohydrate (Merck KGaA,
Darmstadt, Germany), polysorbate 80 (Sigma-Aldrich); PLA2 (DSM, Heerlen, Nether-
lands); purified water (Fresenius Kabi Deutschland GmbH, Bad Homburg); magnesium
stearate (Baerlocher GmbH, Unterschleissheim, Germany).
3.2.2.2 Particle size measurements
The particle size of phosphatidylcholine powder was measured in triplicates by pow-
der laser diffraction (Sympatec
®
Helos Rodos GmbH, Clausthal-Zellerfeld, Germany)
after eliminating particles larger than 850 micrometer by sieving (Fritsch GmbH, Idar-
Oberstein Germany).
3.2.2.3 Powder densities and flow properties
The bulk and tapped densities were determined by filling 100 g powder into 250 mL
measuring cylinder undergoing 1250 taps (ErwekaGmbH,Heusenstamm, Germany) and
were calculated as ratio of powder weight to volume occupied before and after tapping,










where, ρtapped is the tapped density and ρbulk is the bulk density. The angle of repose was
measured with Erweka Powder Flow tester (Erweka GmbH, Heusenstamm, Germany).
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3.2.2.4 Preparation of tablets
The phosphatidylcholine powder (sieve fraction 90-180 µm) was blended with the drug
for 10 min in a Turbula mixer (Willy A. Bachofen AG, Basel, Switzerland). The drug
loadings ranged from 10 to 90% w/w. Then, 1% w/w magnesium stearate was added
to the blend and further mixed for 3 min. The powders were compressed into 8 mm
diameter, flat-faced tablets (160 ± 2 mg) at pressures ranging from 5 to 400 MPa using
a single punch tablet press at 10 rpm (Korsch EK0, Korsch AG, Berlin, Germany). The
compression force was recorded (MGCplus, Catman, HBM Inc, USA). Tablets prepared
with the powder particle size fractions 0- 90 µm and 180 -315 µm were used to study
the effect of particle size on drug release. Placebo tablets were prepared by compressing
phosphatidylcholine powder into 11 mm flat-faced tablets with a compaction simulator
(Huxley Bertram, Cambridge, UK) at pressures ranging from 5 to 210 MPa and dwell
time of 23 millisec. Data acquisition was recorded with a time interval of 0.02 millisec.
The plastic work of compaction was calculated as the area under the curve of the force-
displacement diagram with MS Excel software, applying the trapezoidal approximation
method. The compensated upper punch position was used in calculations.
3.2.2.5 Tablets characterization
The tablet thickness and the diameter were measured by an electronic micrometer (± 0.01
mm, Digi-Met; Helios Preisser, Gammertingen, Germany). The weight was recorded (±
0.1 mg; Mettler AT200) 24 h after compression. The tablet breaking force was measured
on a tablet hardness tester (Multicheck, Erweka GmbH, Heusenstamm, Germany), and





where σ is radial tensile strength [MPa]; F is breaking force [N]; d is tablet diameter [mm]; h is
tablet thickness [mm].
The tablet porosity was calculated as the ratio of apparent and true density. The true den-
sity of phosphatidylcholine was determined by the method described by C. Sun, (Sun,
2005), where the compaction pressure and tablet apparent densities are fitted into the
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non-linear regression of the modified Heckel equation (Kuentz and Leuenberger, 1999)
(Eq. 7, Appendix). The method was validated with Avicel
®
102, and the results were in
accordance with published data (Fig.34 Appendix).
3.2.2.6 Determination of the degree of phospholipid hydrolysis in incubationmedium
with PLA2
Incubation buffer was prepared as follows: 6.11 g of β-(N-Morpholino)ethanesulfonic
acid (MES) monohydrate, 6.19 g of NaCl and 0.15 g of polysorbate 80 were dissolved
in purified water. The pH was adjusted to 6.50 with 0.1 M solution of NaOH. Water
was added to give a total volume of 1.0 L of buffer solution. Calcium acetate (1 g) was
dissolved in 40 ml of the buffer solution, matrix tablet and PLA2 (44,372 U) were added
and the resulting mixture was stirred at 37°C. Samples were taken after 2 h, 4 h, 6 h, 8
h and 24 h and analyzed by thin layer chromatography (TLC). After 24 h the tablet was
removed from the medium by filtration, rinsed with water and lyophilized to determine
the dried tablet weight.
3.2.2.7 Drug release
Drug release was performed using a USP paddle apparatus (900 mL, hydrochloric acid
solution pH 1.2 and pH 2, phosphate buffer pH 3, 0.05 M phosphate buffer pH 4.5 and
0.05 M phosphate buffer pH 6.8 at 37°C, 75 rpm, n=3). (VK 7000, Agilent Technolo-
gies Deutschland GmbH, Böblingen, Germany). Sodium chloride was added to adjust
the osmolality. Samples were taken at predetermined time points and analysed UV-
spectrophotometrically (λ=273 nm).
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3.2.3 Results and Discussion
3.2.3.1 Phosphatidylcholine powder characterization and tabletabilty
Good powder flow and compactibility are obligatory requirements for excipients for
direct compression to ensure process reproducibility and product quality. The particle
shape and size distribution were analysed since powder flowability is a consequence of
the combined effects of various physical, chemical and environmental variables (Schulze,
2008). The particle size distribution of phosphatidylcholine powder contained a primary
mode centering around 100 µm and a minor mode around 475 µm (Figure 24). The d50
was 102.0 ± 0.71 µm. The particles were spherical (Figure 24).
Figure 24. Particle size distribution measured by powder laser diffraction (A) and optical mi-
croscopy picture of phosphatidylcholine powder (B).
Phosphatidylcholine powder had good flow properties according to USP [1174] (Table
16) with a Carr index of 12.6, a Hausner ratio of 1.15 and an angle of repose of 28.8, thus
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being suitable for direct compression.



































The ability of saturated phosphatidylcholine to form compacts by compression was eval-
uated. Compacts of the pure excipient were characterized by a relatively low tensile
strength and a low friability ( 0.1%). The tensile strength was independent of compaction
pressure above 40 MPa. The porosity of tablets decreased with increasing compaction
pressure up to about 40-50 MPa, thereafter, tablets approached to close to 0% porosity
(Figure 25).
Figure 25. Compactibility profile of saturated phosphatidylcholine powder: (A) tensile strength
(B) air porosity as a function of compaction pressure with (C) enlarged initial porosity
scale.
The work of compaction spent for irreversible plastic deformation in absolute terms was
independent of the compaction pressure above 30-40 MPa, as determined from punch
force-displacement curves (Figure 26 A). The fraction of the plastic work of the total com-
paction energy decreased gradually (Figure 26 B) on the expense of the increasing elastic
recovery of the compact, reaching almost 0% porosity (Figure 26 C).
Only elastic deformation of the compact occurred once the density of thematrices reached
its maximum, which was in line with the observed plateauing of the tensile strength of
the tablets. Diprophylline was formulated with the phospholipid at drug loadings from
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Figure 26. Contribution of plastic work as a function of (A) compaction pressure in absolute terms
and (B) as a % to total work of compaction.
10 to 90% w/w. The effect of drug loading on tablets porosity and tensile strength was
assessed (Figure 27). The porosity of pure diprophylline tablets gradually declined to
6% at 400 MPa. Formulations with 90 and 80% drug loading had similar profiles, reach-
ing 5.5 and 4.9% porosity, respectively. Starting from 70% drug loading, the decrease in
porosity was similar to the phospholipid. Therefore, dense matrices were obtained at low
compression pressure. The tablets tensile strength was independent of the drug loading
in the range of 10 to 50% but overall was higher for drug-containing tablets compared to
pure phospholipid tablets. Tablets with a tensile strength of about 1.5MPawere obtained,
which is usually considered acceptable for conventional tablet formulations (Eyjolfsson,
2014).
Figure 27. Effect of drug loading (A) on resulted air porosity and (B) tablet tensile strength as a
function of compaction pressure.
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3.2.3.2 Effect of drug solubility on drug release
The release from tablets prepared from blends of theophylline, caffeine or diprophylline
and phospholipid (30:70 w/w) was studied (Figure 28). As expected, a higher drug sol-
ubility resulted in faster drug release due to the higher concentration gradient between
the saturated drug solution formed inside the matrix and the drug concentration in the
dissolution medium. A drug release of 80% was achieved in 3.5 h for diprophylline, 6
h for caffeine and 24 h for theophylline. This reflects that retardation is feasible with
phospholipid matrices.
Figure 28. Effect of drug solubility on the release from phosphatidylcholine matrix at drug: lipid
30:70 weight ratio in phosphate buffer pH 6.8.
3.2.3.3 Effect of drug loading on drug release
One of the main formulation factors influencing drug release of matrices is drug loading
(Frenning, 2011).
The caffeine release increasedwith increasing drug loading and typical diffusion-governed
dissolution profiles were obtained (Figure 29). The tablets maintained their integrity dur-
ing release up to 50% drug loading, at higher loadings, an increased surface erosion was
visually observed. Time to 80% drug release varied from 1.5 h for formulation with 70%
drug loading to 18 h for 10% drug loading. Thus, a wide range of release patterns was
achievable.
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Figure 29. Effect of caffeine loading on drug release from saturated phosphatidylcholine matrix
tablets in phosphate buffer pH 6.8.
3.2.3.4 Effect of tablet size on drug release
Tablet dimensions affect the drug release from insoluble matrices (Siepmann, 2008). The
drug release decreased with increasing matrix diameter resulting in t80 of 1, 2 and 4 h
(Figure 30).
Figure 30. Effect of tablet size on caffeine release from saturated phosphatidylcholine matrix
tablets in phosphate buffer pH 6.8 (60% drug loading); the closed symbols represent
experimental results; the curves represent calculated release.
The experimental data fitted well to the appropriate solution of Fick’s second law of
diffusion (Eq. 6) (R
2
0.94-0.98), considering the given initial and boundary conditions
(Vergnaud, 1993).




/s) for tablets with different
dimensions, which was in line with a diffusional release mechanism. Tools for adjusting




















where Mt and M∞ are the absolute cumulative amounts of drug released at time t, and infinite
time, respectively; qn are the roots of the Bessel function of the first kind of zero order [J0(qn) =
0], and R and H are the radius and height of the cylinder.
to desirable drug release were elucidated: Smaller dimensions and higher drug loadings
are more appropriate for poorly soluble drugs, and vice versa for more soluble drugs.
3.2.3.5 Formulation robustness with regard to drug release
The effect of particle size of phospholipid powder on caffeine release from matrix tablets
was studied with three phospholipid size fractions / sieve cuts: 0-90 µm; 90-180 µm and
180-315 µm.
Figure 31. Effect of particle size of phospholipid powder on caffeine release in phosphate buffer
pH 6.8 (60% drug loading).
Tablets produced from the fine powder fraction (0-90 µm) resulted in a slower drug re-
lease, with 80% drug being released in 5 h, compared to 2 and 1 h for the fractions 90-180
and 180-315 µm, respectively (Figure 31). Smaller particles thus produced a tighter ma-
trix with smaller pores, hindering the penetration of release medium and drug diffusion.
Moreover, tablets compressed from powders with a larger particle size were more prone
to erosion, which was in accordance with literature findings (Barra, Falson-Rieg, and
Doelker, 2000; Caraballo, Millan, and Rabasco, 1996). Therefore, the use of the fine parti-
cles fraction of the phospholipid is recommended for extended release formulations.
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Although, the digestion of a phospholipid-based matrix tablet is rather unlikely due to
very limited surface area exposed to enzymes, hydrolysis by mainly phospholipase A2
(PLA2) was reported for small particles in the duodenum (Massing Ulrich, 2008). To in-
vestigate a potential risk for the integrity of the release controlling phospholipid matrix,
an in vitro study was performed to assess the stability of saturated phosphatidylcholine-
based matrix tablets against PLA2-mediated hydrolysis and against detergents, simulat-
ing bile salt/phospholipid mixed micelles.
The tablet weight loss due to diacyl phosphatidylcholine hydrolysis was normalized by
initial moisture content (1.9%) and weight loss due to tablet erosion (0.3%) in incubation
medium. As determined by TLC, 4% of the total mass of phospholipids in the matrix
tablets were hydrolyzed to free fatty acids and monoacyl- phospholipids after 8 h incu-
bation at 37°C and 10 - 15% after 24 h (Table 17). Overall, the matrix tablets were proved
to be stable up to 8 h of exposure to GI tract medium at 37°C.
Table 17. Degree of PLA-mediated hydrolysis of placebo phospholipid tablets.
Sampling time, h 2 4 6 8 24
Free fatty acids, % 1 2 2 4 14
Monoacylphospholipids, % n.d. n.d. n.d. 4 10
n.d. = not detectable (i.e. < 1.1 %)
Tablets with 20% caffeine loading were studied under different dissolution conditions
i.e. pH, ionic strength and agitation speed. Tablet robustness to mechanical stress was
studied at paddle rotation speeds of 50, 75 and 100 rpm (Figure 32).
There was little effect on the initial drug release rate observed at 100 rpm, which could be
attributed to a faster dissolution rate of the drug particles at the tablet surface. Overall,
the matrices were robust in terms of mechanical stress during dissolution testing. The
drug release decreased with increasing pH of the release medium. An about 3-times
faster release of caffeine was observed at pH 1.2 and 2 compared to pH 4.5 and 6.8, with
an intermediate behaviour at pH 3 (Figure 33). Because of the pH-dependent solubility
of caffeine, pH-differences in drug release were attributed to faster hydration of phos-
phatidylcholine matrix, which was in line with a previous study (Fujii et al., 1998). There
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Figure 32. Effect of paddle rotation speed on caffeine release from saturated phosphatidylcholine
matrix tablets (20% drug loading).
was no ionic or osmotic effect involved as similar characteristics were obtained in me-
dia with different ionic strengths (data not shown). Phosphatidylcholine tablets swelled
at low pH, followed by rapid erosion and then tablet disintegration, whereas at pH 4.5
and 6.8, tablets remained intact throughout the release test. The tablet swelling at pH
1.2 was attributed to the protonated phosphate group of the phosphatidylcholine, result-
ing in a net positive charge at the choline group and hence a higher hydrophilicity. This
pH-dependent release could potentially be beneficial in some cases for oral drug delivery
(taste masking, pH-dependent drug solubility). The inclusion of gastroresistant excipi-
ents could be a way to obtain a more et pH-independent release.
Figure 33. Effect of pH on caffeine release from saturated phosphatidylcholinematrix tablets (20%
drug loading).
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3.2.4 Conclusions
The evaluation of saturated phosphatidylcholine as a direct compression excipient was
performed. The phospholipid powder had good flow properties and a good compactibil-
ity due to its high plasticity. Tablets with very low porosity were formed with up to 70%
drug loading. Extended drug release could be achieved with drugs with different solu-
bilities, combining different drug loadings and tablets sizes. The drug release was robust
to media ionic strength and mechanical forces; however, a pH-dependent release was
observed.
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where P is compaction pressure, C is constant indicating the deformability, εc denotes critical
state, where mass starts to gain rigidity or strength.
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Figure 34. Determination of powder true densities by fitting experimental data into non-linear
regression; (A) Avicel 102, (B) Phospholipon 90H.
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3.3 pH-dependent Behaviour of Phosphatidylcholine: Mecha-
nism Elucidation and Approaches to Minimize It
3.3.1 Background
The main goal of extended drug delivery is to maintain effective drug concentration in
blood through a longer period of time, for drugs with high water solubility and/or short
half-life, thus reducing dosing frequency and preventing therapeutic concentration fluc-
tuations. Therefore, the extended release products optimize therapeutic effect and safety
of a drug and at the same time improve patient convenience and compliance.
Matrix tablets are one of the dosage forms which allow controlled drug release. Gener-
ally, they consist of matrix-forming excipient and dispersed drug, which is released from
matrix network by diffusion through water filled channels and pores and/or additional
matrix erosion. In order to successfully control drug release rate duringmatrix properties
should not change drastically during tablet passage through gastrointestinal tract (GIT).
There, however, is a variety of different conditions met in GIT in physiological condi-
tions, i.e. pH and osmolality fluctuations, presence of bile salts, changes in the intestinal
motility and hydrodynamics, which can significantly impact dissolution and absorption
of the drug.
In order to design pH-independent delivery system, it is important to consider the range
of usual values for GI pH and their variations under normal physiological conditions as
well as understand the drugs and excipients behaviour under these conditions.
There have been numerous studies reported on pH fluctuation and residence time in the
stomach. Although, there is high degree of variability present for gender, age, health con-
ditions, fed or fasted states, it is generally considered that pharmaceutical dosage form
would spent ca. 2 hours in stomach at pH 1-2. Therefore, these conditions were further
adopted for dissolution testing of phosphatidylcholine matrix tablets to evaluate meth-
ods applied to achieve pH independent release.
Furthermore, once mechanism of pH-dependent behaviour was studied in detail, at-
tempts to suitably modify material were made, as well as common formulation adjust-
ments were explored to achieve pH independent release from phosphatidylcholine ma-
trix tablets.
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3.3.2 Materials and Methods
PHOSPHOLIPON
®
90H (Lipoid GmbH, Ludwigshafen, Germany); anhydrous caffeine
(BASF, Ludwigshafen, Germany); hydroxypropyl methyl cellulose phthalate HPMCP
HP 50 (Shin Etsu Chemicals Co., Ltd.); ethyl cellulose EthocelTM Premium 10 cp (Dow
Chemical Co, Midland, MI, USA), Shellac (SSB
®
57 Pharma Flake Shellac), magnesium
hydroxide, sodium dodecyl sulfate, magnesium stearate
3.3.2.1 Phosphatidylcholine powder coupling with chloride ions
Soaking
Hydrochloric acid (0.1N) solution prepared in MilliQ
®
water was poured onto phos-
phatidylcholine powder. 90H powder was recovered by filtering the suspension through
paper filter (Whatman™Grade1) under vacuum and drying in vacuum oven at room
temperature. Conductivity and pHweremeasuredwith corresponding electrodes (Seven-
Multi
TM
dual meter pH/conductivity, Mettler Toledo, Greifensee, Switzerland).
Spray drying
Solutions of phosphatidylcholine (90H) 3% (w/w) with ethyl cellulose or hydroxypropyl
methyl cellulose phthalate (at 10:1 weight ratio) were prepared in 95:5 mixture of iso-
propanol and water. Suspensions of 90H were prepared in calcium chloride (CaCl2)
MilliQ
®
water solution (at 1:1 molar ratio, phosphatidylcholine to calcium chloride). The
following settings were used: inlet temperature, 110-90°C; outlet temperature, 55°C; liq-
uid feeding rate, 5-8 g/min; atomising gas flow rate, 30 m
3
/h and 100% for the aspirator
rate.
3.3.2.2 Tablet preparation
Tablets (8 mm, flat) were prepared with 20 and 60% drug loadings with phosphatidyl-
choline treated or untreated powder or phosphatidylcholine blends with additional ex-
cipients at different w/w ratios on a single punch tabletting press (Korsch EK0, Berlin,
Germany) at 10 kN compression force.
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Dry granulation
Dry granulation was performed by slugging method. Corresponding amounts of caf-
feine and 90H were properly mixed and tableted into 20 mm porous tablets, which were
crashed into granules and classified. Granule size fraction of 180-425 µm was used for
tableting, after adding 1% w/w magnesium stearate.
Wet granulation
Wet granulation was performed in mixer torque rheometer (Caleva, Dorset, England).
Corresponding amounts of caffeine and 90H were weighted and mixed for 10 minutes,
followed by wetting with 6% w/w solution of ethyl cellulose or hydroxypropyl methyl
cellulose phthalate in 88:12 and 80:20 isopropanol:water mixture correspondingly or 10%
w/w shellac solution in ethanol until reaching total amount of 2.5% polymer in formula-
tion. Wet mass was sieved and resulted granules dried in ventilated oven at 40°C.
3.3.2.3 Tablets water uptake
Water uptake by placebo tablets was determined gravimetrically. Samples were incu-
bated in corresponding solutions hydrochloric acid solution pH 1.2 and pH 3 (hydrochlo-
ric acid solution with pH 3 was prepared by suitable dilution of 0.1N solution, sodium
chloride was added to adjust the osmolality (Osmomat 3000, Gonotec, Berlin, Germany)),
acetate buffer pH 3, phosphate buffer pH 3, and pH 6.8 at 37°C and 85 rpm horizontal
shaker. Weight gain in % was calculated as follows:
Water uptake % =
wet weight− dry weight
dry weight
× 100% (Eq. 8)
3.3.2.4 Dissolution testing
Drug release was performed using a USP paddle apparatus (900 mL, hydrochloric acid
solution pH 1.2 and pH 2, phosphate buffer pH 3, 0.05 M phosphate buffer pH 4.5 and
0.05 M phosphate buffer pH 6.8 at 37°C, 75 rpm, n=3) (VK 7000, Agilent Technologies
Deutschland GmbH, Böblingen, Germany). Samples were taken at predetermined time
points and analysed UV-spectrophotometrically (λ=273 nm).
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3.3.3 Results and Discussion
3.3.3.1 Elucidation of underlying mechanism for pH dependent behaviour of phos-
phatidylcholine powder
There was a remarkable difference in drug release rates from saturated phosphatidyl-
choline matrix tablets at different pH (Figure 35 A). Formulations of binary mixtures of
PC and non-ionizable model drug, caffeine, were studied, thus pH dependent drug re-
lease was attributed to the phosphatidylcholine properties. Previously, the differences
in release of paracetamol (another non-ionizable drug) from phospholipid matrices were
related to different hydration kinetics at acidic and neutral pH (Fujii et al., 1998). Wa-
ter uptake study was performed on placebo phosphatidylcholine matrix in hydrochloric
acid solution (pH 1.2) and phosphate buffer (pH 6.8) (Figure 35 A). Indeed, significantly
higher water uptake was observed at pH 1.2 HCl which was in line with drug release
results (Figure 35 B), thus confirming that it was matrix pH dependent hydration rate,
which was responsible for differences in drug release.
Figure 35. Effect of dissolution medium pH on (A) placebo matrix water uptake and (B) caffeine
release from phosphatidylcholine matrix tablet.
Hydration kinetics were further related to the ionization state of PC. Taking a closer look
at the PCmolecular structure of a polar head, two functional moieties could be identified:
phosphate group with apparent pKa 3 (Boggs, 1987) and quaternary ammonium group
(Figure 36). At pH over 3, phosphate group is mainly deprotonated and thus, negatively
charged, while quaternary ammonium is always positively charged, regardless medium
pH, hence PCmolecule is present as zwitterion. On the other hand, in the acidic medium,
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pH < 3, phosphate remains protonated, and PC has only positive charge of quaternary
ammonium group.
Figure 36. Schematic representation of phosphatidylcholine molecule with a net 0 charge. Image
source: Wikimedia Commons, Public domain.
It has been suggested, that in acidic medium the uncompensated positive charge of qua-
ternary ammonium group strongly attracted counterions from the medium, favoringma-
trix hydration and consequently drug release. Drug release from phosphatidylcholine
tablets containing 20% caffeine was performed in different pH media (Figure 37). Re-
sults were in accordance with suggested mechanism of hydration. It was observed that
at the acidic pH (1.2 and 2, HCl) drug release was significantly accelerated compared to
the release in phosphate buffer at pH 4.5 and 6.8, whereas caffeine release rate at pH 3
(phosphate buffer) was intermediate.
Figure 37. Effect of dissolution medium pH on caffeine release from phosphatidylcholine matrix
tablets.
Furthermore, buffer anionic species had strong effect on hydration as it was previously
described for acrylic insoluble polymers (Eudragit
®
RS/RL) with similar quaternary am-
monium cations in the structure (Bodmeier et al., 1996,Wagner and McGinity, 2002). Wa-
ter uptake in different buffers at pH 3 was measured for placebo phosphatidylcholine
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matrix. Similarly to Eudragit
®
RS/RL, the extent of phosphatidylcholine matrix hydra-
tion was proportional to the hydrodynamic radius (i.e. ion hydration shell) of buffer ions
(e.g. acetate > phosphate > chloride) (Figure 38 A) (Simon, 1991).
Figure 38. Effect of (A) buffer anion species and (B) buffer pH on phosphatidylcholine matrix
hydration extent.
Overall, hydration extent of phosphatidylcholine matrix depended strongly on medium
pH which defined ionization status of phosphate group and thus, the degree of quater-
nary ammonium affinity for buffer anions (Figure 38 B) and on the present buffer anionic
species.
3.3.3.2 Phosphatidylcholine powder coupling with chloride ions
In order, to decelerate the ions attraction andmatrix hydration in acidicmedium, material
modification by previous coupling of quaternary ammonium group with chloride ions
was intended. It has been speculated, that associated chloride ions would bring medium
ions exchange rate into equilibrium, rather than uncontrolled ion flux to uncompensated
positive charge of quaternary ammonium group, thus matrix hydration rate could be
slowed down.
Phosphatidylcholine powder treatment with hydrochloric acid
In order to couple quaternary ammonium with chloride ions, the phosphatidylcholine
powder was treated with 0.1N HCl solution in MilliQ
®
water. Solution conductivity
decrease was proportional to amount of PC added, confirming chloride ions uptake by
Chapter 3. Results and Discussion 80
quaternary ammonium groups. Further, to ensure phosphatidylcholine stability in acid
medium, the contact time was greatly reduced to few seconds, by pouring 0.1N HCl so-
lution onto PC powder during the vacuum filtering. To confirm the lack of hydrolysis
due to acidic treatment, FTIR was performed. There was no significant shift in wave-
length corresponding to the ester bond of initial 90H powder to lower frequencies in
treated (90H Cl) powder observed (1728 and 1735 nm, accordingly), which would indi-
cate hydrolysis. The spectrum of palmitic acid was used as a control, presenting peak
corresponding to carboxylic acid at 1700 nm (data not shown) (Pavia et al., 2009).
Finally, drug release from tablets composed of treated phosphatidylcholine powder and
caffeine at 20 and 60% drug loading was compared to untreated phosphatidylcholine
powder formulations. At 60% drug loading, there was similar drug release at pH 1.2 and
pH 6.8 in formulation with treated 90H powder, which contrasted with pH dependent
profile of untreated powder (Figure 39 A). The pH independent release was observed
for first two hours of release, which could potentially be translated into pH independent
drug release in vivo, since gastric transition time is ca. 2 hours (Davis, Hardy, and Fara,
1986).
Figure 39. Caffeine release at (A) 60% drug loading and (B) 20% loadings from tablets composed
of phosphatidylcholine chloride powder at different pH.
At lower drug loading (higher PC content), caffeine release was overall slower both in
acidic medium and in phosphate buffer, however the pH dependent release maintained
(Figure 39 B). The decrease observed in caffeine release rate was in line with initial sug-
gestion that in acidic medium coupled chloride ion prevented massive influx of medium
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ions into matrix and slowed down hydration; while in phosphate buffer – hindered hy-
dration due to higher selectivity of quaternary ammonium group for chloride compared
to phosphate ions (Fritz, 2005).
To estimate the gap in drug release at different pH, the ratio of drug released at 2 hours
in HCl to PB was calculated both for treated and untreated powders. With bigger dif-
ference in drug release, higher ratio would be expected, whereas with pH independent
behaviour it would be equal to 1. In effect, for formulations with 60% drug loading cal-
culated ratio reduced from 1.43 to 1.18 for untreated and treated powders respectively,
while at 20% drug loading, it was 2 for both, thus indicating that coupling 90H pow-
der with chloride ions was a fair option to minimize pH dependent drug release only in
formulations with high drug loadings.
Phosphatidylcholine powder spray-drying with calcium chloride
In order to avoid 90H powder treatment with 0.1N HCl and hence potential hydrolysis,
spray drying of 90H dispersion in calcium chloride MilliQ
®
water solution at equimolar
ratio was performed in mini spray dryer. Very fine cohesive powder with poor com-
paction properties was recovered. Water uptake study on placebo matrix, suggested that
added chloride was not associated with quaternary ammonium, but rather resulted in
physical mixture.
Figure 40. Effect of phosphatidylcholine spray drying with calcium chloride salt on water uptake
at different pH (A); Macroscopic images of precipitated crystals of calcium phosphate
on the placebo matrix surface (B).
Very slight reduction of hydration extent in acidic medium was observed between un-
treated PC powder and spray-dried with calcium chloride (Figure 40 A). Even more,
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there was strong erosion of matrix in phosphate buffer, probably due to calcium phos-
phate precipitation, as it was revealed bymacroscopic images (Figure 40 B). Furthermore,
it was confirmed with conductivity measurements, that no complexation of chloride ion
with quaternary ammonium occurred in non-acidic medium (i.e. while phosphate group
was deprotonated and thus, negatively charged).
3.3.3.3 Formulation adjustment for pH independent release
Since PC powder complexation with chloride ions did not eliminate pH dependent ma-
trix behaviour completely, common formulation adjustments were intended to disguise
it. First, different methods were used to prepare matrix tablets with 60% caffeine loading:
direct compression (DC); dry granulation (DG) and wet granulation (WG)
Figure 41. Effect of tablet preparation methods on caffeine release (60%) from phosphatidyl-
choline matrix tablets at different pH.
Caffeine release rate changed in the following order: direct compression > dry granula-
tion > wet granulation (Figure 41), whereas the pH effect magnitude was very similar for
all methods, ratio of drug released in HCl to PB at 2 hours ranged between 1.4-1.8 for all
methods.
Addition of sodium dodecyl sulphate
The hydration of the materials containing cationic group is influenced by the ions present
in dissolution media (Guo, X.D., Bodmeier, R., Sarabia, R., and Skultety, 1993) and can
be altered by the mechanism of ion exchange. Sodium dodecyl sulphate (SDS) has been
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shown to modify indomethacin release from Eudragit® RS-based matrix tablets by com-
peting for the cationic sites of the latter (Khanfar et al., 1997). Furthermore, it has been
reported that incorporation of up to 5% w/w sodium dodecyl sulphate (SDS) in the coat-
ing membrane of Eudragit RL/RS resulted in substantial increases in lag times in acidic
and neutral media during diltiazem release (Heinicke and Schwartz, 2007).
Sulphate groups have a high affinity for quaternary ammonium and while, fatty acid
chain exhibits interaction to hydrophobic moieties of PC. Therefore, it has been suggested
that SDS could compete with medium anions in order to prevent fast matrix hydration
in acidic medium. Since ion coupling was not feasible at neutral pH (MilliQ
®
water) and
spray drying strongly affected powder properties, SDS was added to formulations as a
physical mixture.
Figure 42. Effect of SDS amount in the formulation on (A) drug release from 20% caffeine tablets
at different pH; (B) extension of drug release in phosphate buffer and on drug release
difference at different pH.
Presence of SDS in formulation had very slight effect on drug release in in acidic medium
and was similar to 90H powder coupled with chloride ions, while, in phosphate buffer
drug release was overall slower for SDS containing formulations. The effect was in-
versely proportional to the amount of SDS added (t80 19, 13 and 11 hours for 1.5, 3 and
6% SDS, respectively, vs. 9 hours for 90H) (Figure 42 B). It was suggested, that dodecyl
sulphate competed with phosphate ions hindering matrix hydration, hence extending
caffeine release, however, at higher SDS content in formulation (6%) release was simi-
lar to 90H, probably due to solubilizing effect of SDS on API. Furthermore, the ratio of
drug released at 2 hours in HCl to phosphate buffer was calculated, advocating that there
should be an optimum SDS concentration in the formulation to effectively minimize pH
dependent drug release.
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Addition of basic agents: magnesium hydroxide
Control over microenvironmental pH inside the matrix was shown as a viable method
to achieve pH independent release of weakly basic and acidic drugs (Doherty and York,
1989; Streubel et al., 2000). In particular, magnesium hydroxide, an insoluble salt of a
strong base, was used to achieve pH independent release for acidic drug (Riis et al., 2007).
It has been suggested, that magnesium hydroxide would react with HCl medium, neu-
tralizing the microenvironmental pH, hence, leading to phosphate group of PC from de-
protonation, and thus, slower matrix hydration. Therefore, tablets with different amount
of magnesium hydroxide (2.5, 5, and 10% w/w) were prepared by direct compression.
Figure 43. Effect of (A) magnesium hydroxide (2.5%) on caffeine (60%) release at pH 1.2 and 6.8;
(B) magnesium hydroxide amount on caffeine (20%) release at pH 1.2; (C) medium
switch after 2 hours from pH 1.2 to 6.8 for formulation with 20% caffeine and 2.5%
magnesium hydroxide.
Addition of magnesium hydroxide to the formulation with 60% caffeine, resulted in pH
independent drug release for 2 hours, very similar as when formulated with 90H pow-
der treated with chloride ions (Figure 43 A). Furthermore, formulations with 20% drug
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loading (i.e. higher PC amount) were tested. Addition of magnesium hydroxide to the
formulation with 20% caffeine had no effect on drug release rate in first 2 hours, how-
ever, prevented tablets from complete disintegration in acidic medium (Figure 43 B). Al-
though, the gap between drug releases at different pH maintained, the preservation of
the matrix integrity allowed overall to achieve extended release, comparable to the one
in phosphate buffer, once the medium was switched (Figure 43 C). Overall, addition of
basifying agent was a viable approach to minimize pH dependent drug release from 90H
matrix tablets.
Addition of insoluble and enteric polymers: ethyl cellulose, HPMCP, shellac
Addition of insoluble and enteric polymers with pH dependent behaviour has also been
regarded as a viable method for adjustment of ionisable drug releases (Dashevsky, Kolter,
and Bodmeier, 2004; Lecomte et al., 2003; Thoma and Ziegler, 1998). Therefore, the use of
the enteric polymers hydroxypropyl methyl cellulose phthalate (HPMCP) and shellac as
well as insoluble ethyl cellulose (EC) was considered.
HPMCP is a cellulose derivative, insoluble in gastric fluid while at pH 5-5.5 (i.e. upper
intestine) it swells and dissolves rapidly (enteric properties). Similarly, shellac is a lac
of natural origin with enteric solubility, regarded as GRAS material, whereas ethyl cel-
lulose is water insoluble at any pH. It was hypothesized that polymers could prevent
matrix swelling in acidic medium and therefore reduce pH effect by partially covering
90H particles in formulation.
Direct compression
90Hwas blendedwith ethyl cellulose (EC) and hydroxypropylmethyl cellulose phthalate
(HPMCP) at 1:1 weight ratio. The powder blend was further formulated into the tablets
with 60% of caffeine prepared by direct compression.
Addition of ethyl cellulose to the formulation resulted in pH independent drug release,
however, it was significantly accelerated, comparable to the one from phosphatidyl-
choline matrix in acidic medium. On the other hand, drug release from HPMCP to 90H
at 1:1 weight ratio minimized the pH gap andwas comparable to caffeine release in phos-
phate buffer (Figure 44 A and B).
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Figure 44. Effect of (A) ethyl cellulose and (B) hydroxypropyl methyl cellulose phthalate addition
to tablet formulation on caffeine release from phosphatidylcholine matrices (60% drug
loading) at different pH.
Wet granulation
To achieve a better coverage of 90H by polymers and to reduce polymers total amount in
the formulation, wet granulation method was investigated to prepare tablets with 60%
caffeine.
Addition of EC or HPMCP did not reduce the pH gap and overall caffeine release was
faster in both media. However, tablets stayed intact (without noticeable erosion) dur-
ing first 2 hours of release, indicating the possibility of extended release (Figure 45 A
and B) once the media is switched. In contrast, shellac performed as expected, reducing
the pH difference between drug releases and maintaining similar extended release as a
control formulation (Figure 45 C). Despite positive outcome, there are several factors to
consider before using shellac. Shellac is natural polymer and its composition and proper-
ties change noticeable with different providers. Furthermore, excipient performance may
be compromised by aging due to storage, not to mention, that it is a colourful (strongly
yellow) material, thus, may require additional coating (Farag and Leopold, 2011).
Spray drying
In order to achieve more effective polymer protection, 90H was spray dried with EC and
HPMCP from alcoholic solution at 9:1 weight ratio and resulted powder was used to
prepare tablets with different caffeine loadings by direct compression.
HPMCP containing formulations resulted in pH independent release at all drug loadings.
EC provided pH independent release for low drug loading (20%) (Figure 46 A). However,
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Figure 45. Effect of (A) ethyl cellulose (B) hydroxypropyl methyl cellulose phthalate and (C) shel-
lac addition to the formulation of 60% caffeine tablet by wet granulation on drug re-
lease at different pH.
with increasing drug loading (60%) release curve had sigmoidal profile (Figure 46 B),
suggesting a rapture of rigid coating-like EC layer due to high osmotic pressure after two
hours of dissolution testing (Bodmeier and Paeratakul, 1994).
3.3.3.4 Alternative excipients
As it has been previously discussed, conventional methods regarding formulation adjust-
ment can further help to disguise pH dependent drug release from phosphatidylcholine
matrices. However, the understanding of the mechanism of pH dependent behaviour
was crucial in order to minimize such effect or completely eliminate it. Once, the pres-
ence of the two ionisable groups in PC structure and in particular, quaternary ammonium
group was identified as a “trouble-maker” in terms of pH, an effort has been directed to
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Figure 46. Caffeine release at (A) 20% drug loading and (B) 60% drug loadings from tablets com-
posed of co-processed phosphatidylcholine (PC) with EC and HPMCP polymers by
means of spray-drying at different medium pH.
Figure 47. Comparison of caffeine release (A) 60% drug loading and (B) 20% drug loadings from
phosphatidylcholine (PC) and phosphatidic acid calcium salt matrices at different
medium pH.
screen for similar “family” excipients which would include the advantages of hydro-
genated phosphatidylcholine, lacking its pH sensitivity.
Hydrogenated phosphatidic acid calcium salt has been identified as such excipient. The
hydrogenation of fatty acid side chains allowed the material to stay in suitable powder
form, the absence of quaternary ammonium group excluded pH dependent hydration,
while calcium salt assures insolubility of material, thus, its potential suitability for pro-
viding extended drug release.
As it was speculated, caffeine release from hydrogenated phosphatidic acid calcium salt
was pH independent at all drug loadings and was remarkably slower than from phos-
phatidylcholinematrix (Figure 13), potentially promising ability to sustain release of very
water-soluble drugs at increased matrix loadings as well.
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3.3.3.5 Outlook
In this work the main effort was made to “correct” pH dependent behaviour of phos-
phatidylcholine in order to assure its extended release matrix forming qualities. How-
ever, it might be interesting, in contrary, to further explore described effect e.g. for taste
masking formulation approaches or enhancing solubility of weakly acidic drugs (e.g.
NSAID), as well as to consider PC as a candidate for parenteral matrix drug delivery
systems.
3.3.4 Conclusions
The mechanism of pH dependent hydration of phosphatidylcholine matrices was eluci-
dated and discussed. Several approaches to minimize apparently pH dependent drug
release have been suggested, both including modifications of initial phosphatidylcholine
powder, as well as conventional formulation adjustments. Although, none of proposed
methods alone offered complete solution in vitro (e.g. at low drug loadings, compromised
powder properties, flow and compactability, etc.), some approaches had promising re-
sults, which potentially could result in suitable in vivo performance.
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3.4 Evaluation of Hydrogenated Soybean Phosphatidylcholine
Matrices Prepared byHotMelt Extrusion for Oral Controlled
Delivery of Freely Soluble Drugs
Abstract
The aim of this study was to prepare controlled release matrices from hydrogenated soy-
bean phosphatidylcholine powder by hot melt extrusion for oral drug delivery of water-
soluble drugs. The liquid crystalline nature of phosphatidylcholine allowed its extrusion
at 120°C, which was below its capillary melting point. Model drugs with a wide range
of water solubilities (8, 20 and 240 mg/mL) and melting temperatures (160-270°C) were
used. Extrudates with up to 70% drug loading were prepared at temperatures below
the melting points of the drugs. The crystalline states of the drugs remaind unchanged
through the process as it was confirmed by XRD and hot stage microscopy. The time to
achieve 80% release (t80) from extrudates with 50% drug loading were 3, 8 and 18 h for
diprophylline, caffeine and theophylline, respectively. The effect of matrix preparation
method (extrusion vs. compression) on drug release was evaluated. For non-eroding for-
mulations, the drug release retarding properties of the phosphatidylcholine matrix were
mostly not influenced by the preparation method. However, with increasing drug load-
ings, compressed tablets eroded significantly more than extruded matrices, resulting in 2
to 11 times faster drug release. Diffusion was identified as the main mechanism of drug
release from phosphatidylcholine extrudates. There were no signs of erosion observed in
extrudates with different drugs up to 70% loadings. The mechanical robustness of phos-
phatidylcholine extrudates was attributed to the formation of a skin-core structure and
was identified as the main reason for the drug release controlling potential of matrices
produced by hot melt extrusion.
Keywords
Hydrogenated soybean phosphatidylcholine; hot melt extrusion; extended release ma-
trix; mathematical modelling; oral controlled release
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3.4.1 Introduction
In oral drug delivery, the control over drug release rates from the dosage forms is of-
ten achieved by application of coatings or by formulation of matrix systems. A variety
of swellable or non-swellable synthetic polymers are used as matrix-forming excipients
with some being suitable for controlling the release of drugs over a broad range of drug
solubility and drug loading (Grund et al., 2014; Maderuelo, Zarzuelo, and Lanao, 2011;
Roberts et al., 2015).
Hydrogenated soybean phosphatidylcholine was recently investigated as a promising
excipient to form matrix tablets by direct compression (Kolbina, Bodmeier, and Körber,
2017). Besides its natural origin, it is chemically defined and available in pharmaceutical
grade quality (Hoogevest, 2017). Hydrogenated soybean phosphatidylcholine powder
had excellent flow properties, processability by compression as well as sufficient poten-
tial to extend release of water-soluble drugs. However, the ability to control release of
highly soluble drugs was compromised due to matrix erosion / disintegration at higher
drug loadings (>30%).
The preparation of matrices by thermal processing techniques has been regarded as more
efficient to control release of water-soluble drugs compared to direct compression due to
the formation of less porous, tortuous matrices. The drug release mechanism from ethyl
cellulose (EC) matrix tablets prepared by either direct compression or hot melt extru-
sion of binary mixtures of water-soluble drug (guaifenesin) and the polymer was inves-
tigated by (Crowley et al., 2004). Further, an extended release with up to 50% diltiazem
hydrochloride was achieved from pellets prepared by hot melt extrusion with ethylcel-
lulose, cellulose acetate butyrate, poly(ethylene-co-vinyl acetate) and polymethacrylate
derivatives (Follonier, Doelker, and Cole, 1994). Hydrophobic lipids and waxes with low
melting points have also been used to prepare controlled-release oral dosage forms by
hot melt extrusion. The dissolution mechanism from lipophilic matrices prepared by hot
melt extrusion is mainly governed by diffusion (Güres et al., 2012;Siepmann et al., 2006),
whereas release kinetics depended on physicochemical properties (such as swelling abil-
ity and solubility) of added rate-controlling agents (Sato et al., 1997).
The effect of drug loading and the type of lipid excipient on drug release was investigated
by De Brabander et al., 2000. Microcrystalline wax with different melting temperatures
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was used as a matrix excipient for melt granulation of ibuprofen. In vitro drug release
rate decreased with decreasing drug loading and with increasing melting temperature of
wax used. Furthermore, effects of different formulation parameters on drug release from
tablets compressed from hot melt granules and those, prepared by high shear melt gran-
ulation, were studied (Liu, Zhang, and McGinity, 2001). Tailored release of paracetamol
from calcium stearate pellets prepared by hot melt extrusion was achieved by addition
of plasticizers, glyceryl monostearate (GMS) and tributyl citrate (Roblegg et al., 2011).
Furthermore, to achieve flexible individual dosing, extended release formulations with
co-extruded wax coating were prepared (Laukamp et al., 2015).
Melt extrusion is generally carried out under elevated temperature, therefore, significant
physicochemical changes can take place during the process. Drugs can either be dis-
persed as crystalline particles or dissolved and/or amorphized in the formulation, de-
pending on the miscibility between the drug and various lipid excipients, pore formers,
and processing conditions (Hasa et al., 2011; Vithani et al., 2014). The solubilization of
metoprolol tartrate in stearic acid during melt extrusion was described (Monteyne et al.,
2016). Additionally, combination of stearic acid and high molecular weight polyethylene
oxide (PEO) at different ratios also resulted in different drug release profiles due to the
hindered hydration of the polymer as a result of molecular interactions between the ex-
cipients.
High dose formulations of highly water-soluble drugs were achieved by using lipid ex-
cipients at a low level (less than 15% ) as a thermal lubricant to facilitate the melt gran-
ulation process. The granules were then compressed into sustained-release tablets con-
taining also conventional polymers, such as hydroxypropyl cellulose and ethyl cellulose
as drug release retardants (Nart et al., 2017; Vaingankar and Amin, 2017).
In contrast to triglycerides and synthetic lipids, phosphatidylcholine capillary melting
occurs at very high temperature of 230°C followed by material decomposition, which
could be a hurdle for its thermal processing or the stability of the incorporated drug.
The aim of this study was to evaluate the feasibility of processing hydrogenated soybean
phosphatidylcholine by hot melt extrusion and, furthermore, to evaluate the release rate
controlling potential of the matrices with special attention to high loadings of water-
soluble model drugs.
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3.4.2 Materials and Methods
3.4.2.1 Materials
Hydrogenated soybean phosphatidylcholine containingmainly esterified stearic and palmitic
acid (Phospholipon
®
90H, Lipoid GmbH, Ludwigshafen, Germany), caffeine anhydrous
fine powder, theophylline anhydrous micronized powder, diprophylline (BASF SE, Lud-
wigshafen, Germany), micronized dexamethasone (FagronGmbH, Barsbeuttel, Germany),
magnesium stearate (Baerlocher GmbH, Unterschleissheim, Germany).
3.4.2.2 Thermal Analysis by Dynamic Scanning Calorimetry
Thermograms of phospholipid powder were recorded using a DSC 6000 (PerkinElmer,
Inc. Waltham, MA, USA). Samples of about 10 mg were accurately weighted in 50µL alu-
minium pans. DSC scans were recorded using a heating rate of 10°C/min at an interval
from 25 to 250°C.
3.4.2.3 Preparation of Extrudates
Homogeneous drug and phospholipid blends were prepared at different weight ratios
(10, 20, 30, 50 and 70%) with mortar and pestle. Blends were loaded into a syringe-die
extrusion device (Ghalanbor, Körber, and Bodmeier, 2010), heated at 135°C for 5 to 9 min
depending on the drug to lipid ratio and then extruded manually. Cylindrical matrices
with diameter of 1.1 and 2 mm were obtained and cut in 2 and/or 8 mm extrudates for
further characterization.
3.4.2.4 Characterization of Extrudates
X-ray diffraction (XRD) measurements were performed to evaluate solid state of drugs
after extrusion with hzdrogenated sozbean phosphatidylcholine with PANalytical XPert
PROdiffractometer (Bragg-Brentano geometry, Cu-Kα radiation, PANalytical B.V., Almelo,
The Netherlands). The diffraction angle range was between 10° and 80° 2Θ (data shown
till 40° 2Θ) with a step size of 0.026°.
Scanning electron microscopy (gold sputtering, Quanta 200 SEM, FEI Corporate, Hills-
boro, OR, USA) was used to evaluate the surface morphology of extrudates.
Lightmicroscopy images (Zeiss Axioskop, Carl ZeissMicroscopyGmbH, Jena, Germany)
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were taken to confirm anisotropic behaviour of phosphatidylcholine during thermal tran-
sitions. Temperature control was achieved by hot stage (FP 90 Central Processor, Mettler
Toledo, Greifensee, Switzerland).
Matrix erosion was evaluated by calculating percent of mass recovery of insoluble phos-
phatidylcholine matrix after the completed drug released to initial phosphatidylcholine
mass in the extrudates and/or tablets.
3.4.2.5 Preparation of Tablets
The phosphatidylcholine powder (sieve fraction 90-180 µm) was blended with the drug
for 10 min in a Turbula mixer (Willy A. Bachofen AG, Basel, Switzerland), 1% w/wmag-
nesium stearate was added to the blend and further mixed for 3 min. The powders were
compressed into 8 mm diameter, flat-faced tablets (160 ± 2 mg) at 300 MPa using a single
punch tablet press at 10 rpm (Korsch EK0, Korsch AG, Berlin, Germany). The compres-
sion force was recorded (MGCplus, Catman, HBM Inc, USA).
3.4.2.6 Porosity Measurement
The matrix porosity was calculated as the percent ratio of apparent and true densities.
The true density of phosphatidylcholine was determined by helium pycnometer (Accu-
Pyc II1340, Micromeritics Instrument Corp., Norcross, USA).
3.4.2.7 In Vitro Drug Release Studies
Drug release was performed using a USP II apparatus (VK 7000, Agilent Technologies
Deutschland GmbH, Böblingen, Germany). (75-100 rpm, 900 mL, 0.05 M phosphate
buffer pH 6.8 at 37°C, n=3. Samples were taken at predetermined time points and anal-
ysed UV-spectrophotometrically (λ=273 nm for all drugs).
3.4.2.8 Mathematical modelling
Non-linear fitting was performed with Solver Add-in MS Office, applying the least sum
of squares method. f2 values were calculated to assess similarity of calculated and exper-
imentally obtained curves using the following Equation:
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(Rt − Tt)2]−0.5 × 100) (Eq. 9)
where Rt and Tt are the cumulative percentages dissolved at each of the selected n time points, t,
of the reference and the test sample.
f2 values of 50 or higher ensure equivalence of the two considered curves; a value of
lower than 50 indicates significant difference between two curves (Shah et al., 1998).
3.4.3 Results and Discussion
3.4.3.1 Thermal characterization of saturated phosphatidylcholine in dry state
Phosphatidylcholines arematerials with reportedmelting temperatures of 220-235°C (Koynova
and Caffrey, 1998). Several transitions to liquid crystalline states occur at lower temper-
atures (Chapman, Williams, and Ladbrooke, 1967). To assess extrudability of the ma-
terial and explore temperatures, at which transitions occur, the thermal behaviour of
hydrogenated phosphatidylcholine powder was characterized by differential scanning
calorimetry (DSC).
A number of endothermic events were observed (Figure 48 A). A major endothermic
peak was detected at 125°C, which corresponded to side chains partial melting and thus,
phosphatidylcholine transition to the liquid crystalline state (Chapman, Williams, and
Ladbrooke, 1967). Furthermore, transitions at 145, 160 and 180°C were observed, reflect-
ing further phase transitions. Finally, a small peak was observed at 233-235°C, where the
capillary melting of the phosphatidylcholine was expected (Figure 48 B) (Koynova and
Caffrey, 1998). The considerably lower enthalpy of the melting peak could probably be
explained by material’s already largely fluidized state, and corresponded to the breakage
of ionic network between polar head groups (Williams and Chapman, 1971).
The endothermic peaks of the DSC thermogramwere correlatedwith temperatures, where
visible morphological changes could be observed under a hot-stage microscope (Figure
48 C). At room temperature phosphatidylcholine particle presented characteristic crys-
talline birefringence under polarized light. The intensity of the birefringence decreased
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and the particle shape changed slightly to a more diffuse structure at about 125°C, indi-
cating a certain degree of deformability. With further temperature increase the particle
became more molten (spherical), however, a liquid crystalline character was maintained
up to 235°C, confirming the presence of ordered structures until reaching the capillary
melting of phosphatidylcholine.
Figure 48. DSC thermogram of saturated phosphatidylcholine in dry state coupled with hot stage
microscopy images.
In general, hydrogenated soybean phosphatidylcholine behaved as ansiotropic fluids i.e.
rotated the plane of polarization of light and, at the same time, could flow as a liquid
under applied pressure (Byrne and Chapman, 1964; Ladbrooke and Chapman, 1969;
Williams and Chapman, 1971) and thus, could be potentially extruded at the transition
temperature of liquid crystalline state.
However, due to the natural origin of the material and therefore not completely defined
composition of side acyl chains, reported transition temperatures could vary between
batches, as well as could depend on previous material thermal history, the presence of
ions and, especially, on powder moisture content. The plasticizing effect of moisture
on reducing polymer glass transition temperature as well as melt viscosity is known
for other materials and has been used to enhance the processability of polymers by hot
melt extrusion and other pharmaceutical processes (Bravo-Osuna, Ferrero, and Jiménez-
Castellanos, 2006; Hancock and Zografi, 1997). Although, there was no systematic study
performed, moisture content of the powder appeared to effect the phosphatidylcholine
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powder processability. Hydrogenated soybean phosphatidylcholine powder with initial
moisture content ranging between 1.5 and 2.5% (w/w) was easily processed at 120°C,
whereas powders with moisture content of less than 1.5% (w/w) could not be extruded
with a studied set up (mini-ram extruder) up to 170°C. Molecular mechanisms behind
the observed effect might be explained by the ability of phosphatidylcholine to form cer-
tain mesomorphic phase structures of liquid crystal domains, which could have an effect
on rheology and thus, processability of phosphatidylcholine powder by extrusion. It
has been demonstrated, that also in apparently dry phospholipid powder (< 6% water)
transitions to lamellar, cubic and hexagonal phases (typical for phospholipid water-rich
systems) occurred as a function of water content, however, at significantly higher temper-
atures, i.e. above liquid crystalline transitions (Luzzati, Gulik-Krzywicki, and Tardieu,
1968). The inability to form rod-like mesophases in completely anhydrous phospho-
lipids has also been stated (Chapman, Williams, and Ladbrooke, 1967). Thus, moisture
content in hydrogenated soybean phosphatidylcholine powder is a critical material at-
tribute, which should be further investigated in regard to hot melt extrusion process.
3.4.3.2 Extrudate preparation and characterization
Drug loaded extrudates were prepared at a temperature above the liquid crystal tran-
sition temperature of the hydrogenated phosphatidylcholine but below the drug melt-
ing temperature, thus, no changes in drug crystallinity were expected. The transition of
phosphatidylcholine powder with initial moisture content of 1.5% resulted in sufficiently
plastic viscous mass and allowed successful phospholipid extrusion at 135°C. The model
drugs were selected to cover wide range of water solubility and melting temperatures
(Table 18). Extrudates with up to 50% (w/w) drug loading were prepared with caffeine,
and with up to 70% (w/w) with diprophylline and theophylline.
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Diprophylline 240 162 254 6.41 ± 0.58
Caffeine 20 235 194 12.69 ± 0.20
Theophylline 8 273 180 7.32 ± 0.44
* in phosphate buffer pH 6.8, at room temperature
All matrices could be easily extruded, however, longer heating times were required at
increasing drug loading from 5 to 9 minutes for 10 to 70% loadings, respectively, i.e. ex-
trudates had smooth surfaces, without visible cracks or pores. They were increasingly
white and shiny at increasing amount of dispersed drug (Figure 49). Extrudates at all
drug loadings were not brittle and could be handled without problems during the exper-
iments.
Figure 49. Macroscopic pictures of extrudates: (upper) placebo saturated phosphatidylcholine
(lower) 50% theophylline loaded extrudate.
XRDwas performed on extrudates to characterize the drugs’ crystallinity before and after
the extrusion process below their melting temperature. Unchanged peak characteristics
gave no indication for any polymorphic transformation of the drug. The resulting extru-
dates were thus, composed of crystalline drug particles of its original polymorph (anhy-
drous caffeine in form II) dispersed in a (recrystallized) matrix of phosphtatidylcholine
(Figure 50).
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Figure 50. Powder X-ray diffraction pattern of caffeine - phospholipid extrudate with 50%
drug loading, caffeine - phosphatidylcholine powders physical mixture (50%), phos-
phatidylcholine and caffeine.
Furthermore, to confirm the absence of potential solubilizing effect of molten acyl chains
of phosphatidylcholine during extrusion, physical mixtures of caffeine and phospholipid
were observed under polarized light on the hot stage microscope. During heating the
powder blends up to the processing temperature, the transition of the phospholipid to
liquid crystalline state could be observed, however, drug crystals remained undissolved
(data not shown). Similar XRD and hot stage microscopy results were obtained with
theophylline and diprophylline. Thus, no effect on drugs’ crystallinity and hence solid
state was seen during extrusion with hydrogenated soybean phosphatidylcholine.
3.4.3.3 Dissolution performance
Drug release from extruded matrices at different drug loadings and water solubility was
studied. The times to achieve 80% release (t80) from matrices loaded with 10% drug were
3, 12 and 24 hours for diprophylline, caffeine and theophylline, and for matrices with
50% drug loadings they were 3, 8 and 18 hours, respectively (Figure 51). Release rates
were decreasing with decreasing drug water solubility and drug loadings. Interestingly,
with matrices loaded with highly soluble diprophylline, no appreciable changes in re-
lease rates with increasing drug loading were observed.
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Figure 51. Experimental (symbols) and fitted (dotted lines) drug release profiles from extrudates
with 10 and 50% loadings of diprophylline (□, ■) (radius (R)=0.5 and height (H)=8
mm) and caffeine (△, ▲) (R=1 and H=2 mm), respectively; and 30 and 50% loadings
of theophylline (○, ●) (R=1 and H=2 mm).
The experimental release data could be well approximated to the mathematical solution
of Fick’s second law of diffusion (Eq. 10 by Vergnaud, 1993), indicating that main mass
transport mechanism was diffusion. The applicability was supported by the observa-
tion of constant matrix dimensions, hence absence of matrix erosion and/or remarkable




















where Mt and M∞ are the absolute cumulative amounts of drug released at time t, and infinite
time, respectively; qn are the roots of the Bessel function of the first kind of zero order [J0(qn) =
0], Dapp apparent diffusion coefficient, and R and H are the radius and height of the cylinder.
Furthermore, the correlation of the apparent diffusion coefficients obtained from Equa-
tion Eq. 10 and the aqueous solubility of the drugs (Figure 52) showed behaviour similar
to what was previously observed for drug matrices based on the synthetic polymer Kol-
lidon SR (Grund et al., 2013) and was also in agreement with other reports, stating that
drug solubility strongly affected drug release rate up to a certain extent, beyond which
the release from the matrix system was less dependent on drug solubility (Harland et al.,
1988; Yang and Fassihi, 1997) (Figure 52).
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Figure 52. Effect of drug solubility on apparent diffusion coefficient from extruded phosphatidyl-
choline matrices at 50% drug loading.
3.4.3.4 Effect of matrix preparation on drug release
To evaluate the impact of matrix preparation method, the drug release of matrices pre-
pared by either extrusion (1 or 2 mm diameter) or by direct compression (8 mm diameter)
were compared at different drug loadings. The release profiles were normalized for ac-
tual matrix dimensions, by calculating apparent diffusion coefficients from the individual
release profiles according to Eq. 10 in order to account for the dimensional differences
between tablets and extrudates.
Previously, the slower drug release from hot melt extruded matrices in comparison to
tablets was described for ethyl cellulose matrices, which was attributed to a reduced
porosity of extrudates (Crowley et al., 2004). In case of phosphatidylcholine, although,
the air porosity was indeed slightly lower in extrudates (no more than 1% vs. 2-4% for
tablets loaded with 10-50% caffeine), calculated Dapp of extruded and compressed matri-
ces resulted in very similar values for non-eroding formulations (caffeine10% and theo-
phylline 30%) (Table 19), indicating that matrix retarding capacity was not influenced
by the used preparation method. In contrary, for formulations with 50% drug loadings,
the calculated Dapp values were 11, 7 and 2 times lower for diprophylline, caffeine and
theophylline matrices prepared by hot melt extrusion, respectively.
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Drug Drug loading, %
Extrudates Tablets
theophylline 30 1.11 0.72
caffeine 10 3.21 3.35
diprophylline 10 6.69 11.22*
theophylline 50 2.23 4.62*
caffeine 50 4.07 37.0*
diprophylline 50 10.81 126*
*compressed matrices eroded significantly, therefore the Dapp values were only calculated for
comparison reasons
A reason for higher retardation capacity of extruded matrices could be the complete lack
of erosion at all drug loadings observed during dissolution testing. To evaluate the effect
of matrix erosion on release rate, 10% diprophylline tablets with early onset of erosion
were compared to corresponding extrudates. While the initial phase of release was gov-
erned by diffusion and was in agreement with predicted profile, calculated based on
non-eroding extrudate, further deviation of experimental release illustrated accelerating
effect of matrix erosion on drug release (Figure 53 A).
Figure 53. Drug release from (A) 10% and (B) 50% loaded diprophylline tablets and extrudates
with identical composition. Open symbols (◇) with solid line represent experimental
and fitted drug release from extrudates (R=0.5; H=8mm), open symbols (○) and dotted
lines – experimental and predicted release from tablets (R=4; H=2.8 mm), respectively.
Additionally, to evaluate controlling potential of extruded phosphatidylcholine matrices
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same calculations were performed for 50% diprophylline tablets (Figure 53 B). In order,
to observe erosion driven S-shape release profile from tablets, time-axes were enlarged,
and therefore significantly slower release from extruded matrices was not shown. The
gap between experimental release from tablets and the prediction based on non-eroding
extrudate, indicated the control gained over the drug release, once matrix integrity could
be preserved through the dissolution testing, and which was successfully achieved by
phosphatidylcholine extrusion.
Thus, the mechanical resistance to erosion through a wide range of drug loadings and
solubility was the main reason for the release controlling potential of extruded phos-
phatidylcholine matrices, while slightly reduced air porosity did not primarily affect
drug release.
3.4.3.5 Erosion of phosphatidylcholine matrices
To establish the extent of extrudate resistance to erosion, the phospholipid matrix recov-
ery (% w/w) after complete drug release was determined for caffeine and diprophylline
extrudates and compared with tablets (Figure 54). Caffeine tablets showed no erosion
up to 30% drug loading. The weight of insoluble phospholipid fraction remaining after
the completed drug release was recovered fully (approx. 100%), followed by gradual de-
crease in recovery at increasing drug loadings (85.5 ± 3.7 and 52.3 ± 13.9% for 40 and
50% caffeine loading), while at 70% drug loading, tablets completely disintegrated and
no matrix could be collected. In contrary, extruded matrices were fully recovered after
completed drug release at drug loadings up to 70%.
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Figure 54. Effect of drug loading on phospholipid matrix recovery for 8 mm caffeine tablets (*)
and extrudates with caffeine (○) and diprophyline (△).
The remarkable mechanical strength and, in particular, the resistance to erosion of ex-
truded matrices was attributed to a high degree of molecular interaction of molten acyl-
chains during processing. Scanning electron microscope images of extruded matrices
after completed drug release showed a highly interconnected network (axial direction)
with pores of about 20-30 µm probably corresponding to previous drug clusters (Figure
55 A1 and A2). The radial surface, however, remained smooth and tight with just small
pores of few µm diameter (Figure 55 B1 and B2), representing a skin-core structure of
extruded matrices, which could explain its mechanical resistance to erosion.
On the other hand, in compressed matrix very limited interparticulate bonding between
deformed phospholipid particles was observed, confirming matrix susceptibility to ero-
sion (Figure 55 C1 and C2). It was believed, that due to its liquid crystalline nature, molten
domains of phosphatidylcholine were stretched by elongational flow, and rod-like acyl
chains become aligned to the flow direction during extrusion, yielding indistinct bound-
aries, while being attached to phosphate choline head which maintained high degree
of order. Similar behaviour during extrusion was studied and described in detail for
thermotropic liquid crystalline polymers, where it has been associated with enhanced
mechanical properties of final extrudates (Ide and Ophir, 1983; Weiss, Huh, and Nicolais,
1987).
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Figure 55. SEM images of 30% caffeine matrices at 600x magnification. From left to right: Ex-
truded matrix cross section surface: (A1) before dissolution and (A2) after the com-
pleted drug release; Extruded matrix side surface (B1) before dissolution and (B2) after
the completed drug release; Compressed matrix cross section surface (C1) before dis-
solution and (C2) after the completed drug release.
3.4.4 Conclusions
Hydrogenated soybean phosphatidylcholine powderwas extruded at a temperature lower
than its capillary melting point, due to its liquid crystalline nature. Release controlling
matrices could be prepared by extrusion with up to 70% loadings of micronized drugs
and no changes in their solid state were observed. Phosphatidylcholine matrices pro-
duced by hot melt extrusion resulted mechanically stronger and denser compared to di-
rectly compressed tablets and thus, were capable of effective retardation of highly water-
soluble drugs at elevated drug loadings for oral delivery. Diffusional mass transport was
assured by complete lack of erosion of extruded phosphatidylcholine matrices at all drug
loadings, and therefore, was the main mechanism controlling drug release.
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4 Summary
In this work, phospholipids (PL) were evaluated as functional excipients for oral deliv-
ery of solid dosage forms. The processability of lecithins with different phospholipid
fractions into solid dosage forms and the performance of hydrogenated phosphatidyl-
choline as matrix forming excipient were studied.
Different manufacturingmethods to obtain free-flowing powders of unsaturated and sat-
urated phospholipids were evaluated as well as physical and rheological characteristics
influencing the tabletability of the powders were studied.
The study of the physical characteristics of the phospholipids revealed that at room con-
ditions (25°C, RH 40%) unsaturated phospholipids were in amorphous or partially crys-
talline state. Moisture sorption profiles suggested that saturated phospholipids could
be considered as slightly hygroscopic substances (less than 20% moisture content after
storing at RH over 90%). On the other hand, unsaturated phospholipids were classified
as moderately hygroscopic substances (less than 40% moisture content after storing at
RH over 80%). Moreover, small amounts of absorbed moisture (3-5%) irreversibly con-
verted phospholipid aggregates into a semisolid mass, which was inadequate for further
powder processing. Special packaging and storing conditions (refrigeration, desiccator
chambers and aluminum sacs) were needed for these materials.
Direct compression could be performed on saturated phospholipids, which were deliv-
ered as fine powders, had adequate flow properties and could be processed into tablets
with sufficient crashing strength (1.5 -2 MPa) at more than 50% phospholipid content
with or without addition of other tableting excipients. To process unsaturated phospho-
lipids into a powder, wet granulation with ethanol was found to be a feasible process.
Granules with up to 30% phospholipid contents were obtained by this method, and fur-
ther could be compressed into tablets with up to 15% loadings. Themain limitations were
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the softness of the resulting tablets and the tendency for punch-sticking during the com-
pression. To maximize the content of unsaturated phospholipids in the resulting powder
(i.e. in the final dosage form), the adsorption of phospholipid ethanolic solution onto







) were used as carriers. Free flowing powders
(i.e. granules) were obtained with up to 60% unsaturated phospholipids. Corresponding
tablets with up to 50-60% phospholipid content and reasonable hardness could be manu-
factured with or without additional tableting excipients. Moreover, Aeroperl-based S 45
powder had a lower equilibriummoisture content than corresponding unformulated S 45
(2.0 vs. 4.8%, respectively), which converted into semi-solid mass after 3 months storing
at room RH in closed bottles, indicating a lower sensitivity for environmental humidity.
Further, saturated phosphatidylcholine (PHOSPHOLIPON
®
90 H) was evaluated as ma-
trix forming excipient for extended drug release. A number of formulation factors which
affect the drug diffusivity (e.g. drug loading, matrix former particle size, tablet porosity,
etc.), and hence the drug release rate, were studied. Direct compression of binary blends
of model drugs (diprophylline, caffeine and theophylline) and phospholipid was used in
order to establish clear cause-effect relationships and to evaluate the general applicability
of this excipient as release retarding matrix-former.
The compactability of saturated phosphatidylcholine was first evaluated. Compacts of
the pure excipient were characterized by a relatively low tensile strength (0.9-1 MPa) and
a low friability ( 0.1%). The tensile strength was independent of the compaction pres-
sure above 40 MPa, which was associated with achieving close to 0% air porosity of the
compact. Similar results were observed for drug:phospholipid blends at different drug
loadings. The tablets tensile strength was independent of the drug loading in the range
of 10 to 50%, but overall was higher for drug-containing tablets compared to pure phos-
pholipid tablets.
Furthermore, extended drug release was achieved with drugs of different solubility and
at various drug loadings. For example, the caffeine release time (t80) from 8 mm tablets
ranged from 1.5 h to 18 h at 70% and 10% drug loading, respectively. The drug release
was governed by diffusion and could therefore be modelled by Fick’s law of diffusion.
Drug release profiles were thus a function of drug solubility, drug loading, and tablet
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dimensions. Matrix tablets of caffeine (20% drug loading) showed robust dissolution
with regard to agitation (50-100 rpm) and ionic strength of the release media (100-600
mOsmol/kg). However, strong pH-dependent behavior of phosphatidylcholine matrix
was observed. Caffeine release was about 3-times faster at acidic pH compared to phos-
phate buffer.
To understand the pH-dependent behavior, the mechanism of saturated phosphatidyl-
choline matrix hydration was studied. Furthermore, methods to resolve or minimize
this effect were evaluated, implying suitable powder modifications and adjustments of
matrix formulation parameters. Differences in phosphatidylcholine matrix hydration ki-
netics at different pH were attributed to the ionization status of the functional groups,
i.e. phosphate (pKa 3) and quaternary ammonium. At pH over 3, the molecule is present
as a zwitterion, while in acidic medium (pH lower than 3) the phosphate group remains
protonated, and phosphatidylcholine has only the positive charge of the quaternary am-
monium group. It has been suggested that in acidic medium the uncompensated posi-
tive charge of the quaternary ammonium group strongly attracted counterions from the
medium, favoring matrix hydration and consequently drug release, which was further
supported by experimental data. Further, it was established that buffer anion species
also had an effect on the extent of matrix hydration, following the order of ion hydration
volume i.e. chloride < phosphate < acetate. The in vitro drug release from phosphatidyl-
choline matrix would thus also be buffer dependent.
The complexation of phosphatidylcholine with chloride ions was intended to reduce the
matrix hydration rate. The results were promising: at 60% drug loadings, formulations
with treated phosphatidylcholine powder resulted in pH-independent drug release for
2 hours. Additionally, numerous formulation parameters were evaluated on the extent
of pH-dependent behavior, e.g. addition of competing anionic species (SDS), basifying
agents (magnesium hydroxide), insoluble and enteric polymers (EC, HPMCP, shellac)
combined with different matrix preparation methods. Although none of the proposed
methods alone resulted in an ultimate solution (e.g. formulations with low drug load-
ings, compromised powder properties, flow and compactability), some approaches had
promising results, which could lead to suitable in vivo performance. Moreover, once the
matrix hydration mechanism was explored, engineering of phospholipid excipients with
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required properties was feasible. Thus, phosphatidic acid calcium salt was explored as a
matrix forming excipient, resulting in pH-independent drug release with retardation ca-
pacity higher than phosphatidylcholine matrix: t80 5 vs. 3 hours for 60% caffeine loading
from PA-Ca and PC 8 mm tablets, respectively.
Finally, the feasibility of processing hydrogenated phosphatidylcholine by hotmelt extru-
sion was evaluated, as well as the release rate controlling potential of resulting matrices
with attention to high loadings of water-soluble model drugs.
The liquid crystalline nature of phosphatidylcholine allowed its extrusion at the tem-
perature of 120°C, which was below its capillary melting point (235°C). Model drugs
with a wide range of water solubility (8, 20 and 240 mg/ml) and high melting tempera-
tures (over 150°C) were used. Extrudates with up to 70% drug loadings were prepared
at temperatures below their melting points, hence the drugs’ solid state remained un-
changed throughout the process, as confirmed by XRD and hot stage microscopy. The
times to achieve 80% drug release (t80) from extrudates with 50% drug loadings were 3,
8 and 18 h for diprophylline, caffeine and theophylline, respectively. This confirmed the
matrix capacity to extend the release of water-soluble drugs at high drug loadings. Fur-
thermore, the influence of the matrix preparation method (extrusion vs. compression)
on drug release from identically composed phosphatidylcholine matrices was evaluated.
Since diffusion was recognised as the main mechanism of drug release, the drug appar-
ent diffusion coefficients were used to compare the performances of different size matri-
ces. Interestingly, non-eroding compressed matrices (drug loadings up to 30%) had very
similar release-controlling potential as the extruded matrices. However, at higher drug
loadings, compressed matrices eroded significantly, resulting in accelerated drug release.
In contrast, extruded phosphatidylcholine matrices had no signs of erosion at any drug
loadings (up to 70%) and solubility. The drugs apparent diffusion coefficient values were
2 to 11 times lower for the extrudates, reflecting their higher retardation capacity. The
mechanical robustness of the extrudates was attributed to the formed skin-core structure
(confirmed by SEM) and was identified as the main reason for the major release control-
ling potential of extruded matrices compared to compressed ones.
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5 Zusammenfassung
In dieser Arbeit wurden Phospholipide als funktionelle Hilfsstoffe für die orale Gabe
von festen Arzneiformen bewertet. Die Verarbeitbarkeit von Lecithinen mit verschiede-
nen Phospholipidfraktionen in festen Arzneiformen und das Verhalten von hydriertem
Phosphatidylcholin als Matrixbildner wurde untersucht.
VerschiedeneHerstellungsmethodenwurden bewertet, um frei fließende Pulver von unge-
sättigten und gesättigten Phospholipiden zu erhalten, und physikalische und rheologis-
che Charakteristika untersucht, die die Tablettierbarkeit der Pulver beeinflussen.
Die Untersuchung der physikalischen Charakteristika der Phospholipide zeigte, dass
ungesättigte Phospholipide bei Raumtemperatur (25°C, 40% RH) in amorphem oder teil-
kristalligeschlossenennemZustand vorliegen. Feuchtigkeitsabsorptionsprofile lassen ver-
muten, dass gesättigte Phospholipide als leicht hygroskopische Substanzen angesehen
werden können (weniger als 20% Wassergehalt nach Lagerung bei relativer Feuchtigkeit
über 90%). Auf der anderen Seite wurden ungesättigte Phospholipide als moderat hy-
groskopische Substanzen klassifiziert (weniger als 40% Wassergehalt nach Lagerung bei
relativer Feuchtigkeit über 80%). Zudem wandelten geringe absorbierte Wassermengen
(3-5%) Phospholipidaggregate irreversibel in eine halbfeste Masse um, die zur weiteren
Pulververarbeitung ungeeignet war. Spezielle Verpackung und Lagerungsbedingungen
(Kühlung, Desiccator und Aluminiumbeutel) waren daher für diese Materialien nötig.
Eine Direktverpressung konnte mit gesättigten Phospholipiden durchgeführt werden,
die als feine Pulver verfügbar sind, adäquate Fließeigenschaften besitzen und in Tablet-
ten mit ausreichender Bruchfestigkeit (1.5–2 MPa) mit mehr als 50% Beladung mit oder
ohne Zusatz von anderen Tablettierhilfsstoffen verarbeitet werden können. Um ungesät-
tigte Phospholipide in Pulver zu verarbeiten, wurde die Feuchtgranulation mit Ethanol
als machbarer Prozess identifiziert. Mit dieser Methode wurden Granulate mit bis zu
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30% Phospholipidgehalt erhalten, und konnten folglich in Tabletten mit bis zu 15% Be-
ladung verpresst werden. Die hauptsächlichen Einschränkungen waren die Weichheit
der resultierenden Tabletten und die Tendenz, während des Verpressvorgangs am Tablet-
tierstempel zu kleben. Um den Gehalt der ungesättigten Phospholipide im resultieren-
den Pulver und damit in der finalen Arzneiform zu maximieren, wurde eine Adsorp-
tion von ethanolischer Phospholipidlösung an porösen Trägern durchgeführt. Silifizierte
mikrokristalline Zellulose (Prosolv
®





) wurden als Träger verwendet. Frei-fließende Pulver (Granulate) mit bis zu 60%
ungesättigten Phospholipiden wurden erhalten. Entsprechende Tabletten mit bis zu 50-
60% Phospholipidgehalt und angemessener Bruchfestigkeit konntenmit oder ohne zusät-
zliche Tablettierhilfsstoffe hergestellt werden. Zudem hatte auf Aeroperl-basierendes
S45-Pulver einen niedrigerenGleichgewichtswassergehalt als das korrespondierende, un-
formulierte S45 (2.0% statt 4.8%), welches nach Lagerung bei Raumbedingungen in ge-
schlossenen Flaschen nach drei Monaten in eine halbfeste Masse umgewandelt wurde,
was eine niedrigere Empfindlichkeit gegenüber umweltbedingter Feuchte zeigt.
Weiterhin wurde gesättigtes Phosphatidylcholin (Phospholipon
®
90 H) als Matrixbild-
ner für Formulierungen mit verzögerter Wirkstofffreisetzung untersucht. Eine Anzahl
von Formulierungsfaktoren, die die Arzneistoffdiffusionsfähigkeit (z. B. Arzneistoff-
beladung, Partikelgröße des Matrixbildners, Porosität der Tabletten, usw.) und damit
die Arzneistofffreisetzungsrate beeinflussen, wurden untersucht. Direktverpressung von
binärenMischungen vonModellsubstanzen (Diprophyllin, Coffein und Theophyllin) und
Phospholipiden wurden verwendet, um klare Ursache-Effekt-Zusammenhänge herzu-
stellen und die generelle Anwendbarkeit dieses Hilfsstoffes als retardierender Matrix-
bildner zu untersuchen.
Die Verpressbarkeit von gesättigtem Phosphatidylcholinwurde zunächst untersucht. Press-
linge bestehend aus reinem Hilfsstoff wiesen eine relative niedrige Zugfestigkeit (0.9-1.0
MPa) und einen niedrigen Abrieb auf. Die Zugfestigkeit war unabhängig vom Verdich-
tungsdruck über 40 MPa, was mit dem Erreichen von nahezu 0% Luftporosität erk-
lärt werden kann. Gleiche Ergebnisse wurden bei Arzneistoff-Phospholipid-Mischungen
erzielt, auch bei verschiedenen Arzneistoff-Beladungen. Die Zugfestigkeit der Tabletten
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war von der Arzneistoffbeladung zwischen 10 und 50% unabhängig, war bei arzneistoff-
beladenen Tabletten aber insgesamt höher als bei reinen Phospholipidtabletten.
Zudem wurde eine verlängerte Arzneistofffreisetzung mit Arzneistoffen unterschied-
licher Löslichkeit und bei unterschiedlichen Arzneistoffbeladungen erreicht. Beispiel-
sweise variierte die Freisetzungszeit von Coffein (t80) bei 8 mm-Tabletten zwischen 1.5
und 18 Stunden bei 70% und 10%Arzneistoffbeladung. Die Arzneistofffreisetzungwurde
durch Diffusion bestimmt und konnte daher mit dem Fick’schen Diffusionsgesetz model-
liert werden. Arzneistofffreisetzungsprofile waren daher ein Resultat aus Arzneistofflös-
lichkeit, Arzneistoffbeladung und Tablettengeometrie. Matrixtabletten mit Coffein (20%
Arzneistoffbeladung) zeigten robuste Freisetzung in Hinsicht auf Rühren (50-100 rpm)
und Ionenstärke des Freisetzungsmediums (100-600 mOsmol/kg). Trotzdem wurde ein
stark pH-abhängiges Verhalten der Phosphatidylcholinmatrix beobachtet. Die Coffein-
Freisetzung war in saurem pH ungefähr dreimal schneller als in Phosphatpuffer.
Um die pH-Abhängigkeit zu verstehen, wurde der Mechanismus der Hydratation der
Phosphatidylcholinmatrix untersucht. WeiterhinwurdenMethoden entwickelt, umdiese
Effekte zu lösen oder zu minimieren, welche passende Pulvermodifikationen und An-
passungen der Formulierung der Matrix implizieren. Unterschiede in den Kinetiken
der Hydratation der Phosphatidylcholinmatrix bei verschiedenen pH-Werten konnten
dem Ionisierungsstatus der funktionellen Gruppen zugeordnet werden, genauer dem
Phosphat (pKa 3) und dem quartären Ammonium. Bei pH-Werten über 3 liegt das
Molekül als Zwitterion vor, während in saurenMedien (pH niedriger als 3) die Phosphat-
gruppe protoniert bleibt, und Phosphatidylcholin nur die positive Ladung vom quar-
tären Ammonium aufweist. Es wurde angenommen, dass in sauren Medien die unkom-
pensierte positive Ladung der quartären Ammonium-Funktion Gegenionen aus dem
Medium anzieht, was dieMatrizenhydratation fördert und so auch die Arzneistofffreiset-
zung, was durch weitere experimentelle Daten unterstützt wurde. Weiterhin wurde
festgestellt, dass die Pufferanionen-Art entsprechend der Reihenfolge des Ionenhydrata-
tionsvolumens (Chlorid < Phosphat < Acetat) ebenfalls einen Einfluss auf das Ausmaß
der Matrixhydratation hatte. Die in vitro Freisetzung aus einer Phosphatidylcholinmatrix
wäre dementsprechend ebenfalls Puffer-abhängig.
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Die Komplexierung von Phosphatidylcholin mit Chloridionen sollte die Matrixhydrata-
tionsrate reduzieren. Die Ergebnisse waren vielversprechend: bei einer Arzneistoffbe-
ladung von 60% konntemit behandeltem Phosphatidylcholinpulver eine pH-unabhängige
Arzneistofffreisetzung über einen Zeitraum von zwei Stunden erreicht werden. Zusätz-
lich wurde der Einfluss zahlreicher Formulierungsparameter auf das pH-abhängige Ver-
halten untersucht, wie beispielsweise der Zusatz von konkurrierenden anionischen Zu-
sätzen (SDS), basifizierenden Mitteln (Magnesiumhydroxid), unlöslichen und magen-
saftresistenten Polymeren (EC, HPMCP, Schellack) in Kombination mit verschiedenen
Matrixherstellmethoden. Obwohl keine dieser Methoden allein zu einer Lösung geführt
hat (z. B. Formulierungenmit niedriger Arzneistoffbeladung, Kompromisse in den Pulver-
und Fließeigenschaften sowie in der Verpressbarkeit), hatten manche Ansätze vielver-
sprechende Ergebnisse, welche zu einem angemessenen in vivo-Verhalten führen kön-
nten. Zudem war die Herstellung von Phospholipidhilfsstoffen mit entsprechend benö-
tigten Eigenschaften möglich, nachdem der Matrixhydratationsmechanismus untersucht
war. Dadurch konnte das Phosphatidsäure-Calciumsalz als Matrixbildner untersucht
werden, welches in einer pH-unabhängigen Arzneistofffreisetzung mit einer höheren
Retardationskapazität als bei einer Phosphatidylcholin-Matrix resultierte: PA-Ca- bzw.
PC-Tabletten (8 mm) resultierten in t80-Werten von 5 bzw. 3 Stunden für eine Coffein-
Beladung von 60%.
Zum Schluss wurde die Machbarkeit der Verarbeitung von hydriertem Phosphatidyl-
cholin mit Hot-Melt-Extrusion untersucht, zusammen mit dem Potential der resultieren-
denMatrix, die Freisetzungsrate in Hinblick auf hohe Arzneistoffbeladungenmit wasser-
löslichen Modellsubstanzen zu kontrollieren.
Der flüssig-kristalline Zustand von Phosphatidylcholin erlaubte die Extrusion bei einer
Temperatur von 120°C, die niedriger war als der Kapillar-Schmelzpunkt (235°C). Mod-
ellsubstanzen mit einem breiten Bereich von Löslichkeiten (8, 20 und 240 mg/ml) und
hohen Schmelzpunkten (über 150°C) wurden verwendet. Extrudate mit bis zu 70% Arz-
neistoffbeladung wurden bei Temperaturen unterhalb ihrer Schmelzpunkte hergestellt,
sodass der Festzustand der Arzneistoffe während des Prozesses unverändert blieb, was
durch XRD und Hot-Stage-Mikroskopie bestätigt wurde. Die jeweiligen Zeiten, um 80%
Arzneistofffreisetzung aus Extrudaten mit 50% Arzneistoffbeladung zu erreichen (t80),
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waren 3, 8 und 18 Stunden für Diprophyllin, Coffein und Theophyllin. Dies bestätigte die
Kapazität der Matrix, die Freisetzung von wasserlöslichen Arzneistoffen bei hohen Arz-
neistoffbeladungen zu verzögern. Zudem wurde der Einfluss der Matrixherstellungs-
methode (Extrusion, Verpressung) auf die Arzneistofffreisetzung bei identisch zusam-
mengesetzten Phosphatidylcholinmatrizen untersucht. Da die Diffusion als Hauptmech-
anismus der Freisetzung angesehenwurde, wurden die scheinbarenDiffusionskoeffizien-
ten der Arzneistoffe verwendet, um das Verhalten der verschiedenen Matrizengrößen zu
vergleichen. Interessanterweise hatten nicht-erodierende verpressteMatrizen (Arzneistoff-
beladungen von bis zu 30%) ein sehr ähnliches freisetzungskontrollierendes Potential
wie die extrudierten Matrizen. Trotzdem erodierten verpresste Matrizen bei höheren
Arzneistoffbeladungen signifikant, was in einer beschleunigten Freisetzung resultierte.
ImGegensatz dazu zeigten extrudierte Phosphatidylcholinmatrizen keine Anzeichen von
Erosion bei allen Arzneistoffbeladungen (bis zu 70%) und Löslichkeiten. Die scheinbaren
Diffusionskoeffizienten der Arzneistoffe waren 2 bis 11-mal niedriger als die der Extru-
date, was deren Retardationskapazität widerspiegelt. Die mechanische Robustheit der
Extrudate wurde der Kern-Mantelstruktur (bestätigt durch SEM) zugeordnet und als
Hauptursache für das überlegene freisetzungskontrollierende Potential der extrudierten
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